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ABSTRACT 
 
 
MAHNAZ SAHRAEIMANOUCHEHRABADI. The role of MUC1 in regulation and 
progression of cancer. (Under the direction of Dr. PINKU MUKHERJEE) 
 
 
           MUC1 is a heavily glycosylated transmembrane glycoprotein which is 
overexpressed and aberrantly glycosylated in most human carcinomas. MUC1 contains a 
large tandem repeat, a short transmembrane, and a small cytoplasmic tail. Both tandem 
repeat and the cytoplasmic tail have been proposed to have significant contributions to 
cellular behavior. In the present study, we have investigated the role of MUC1 in cancer 
progression. First, we have studied the role of MUC1 in oncogenesis during pancreatic 
cancer. Our studies have shown that during pancreatic cancer, MUC1 regulates 
expression of PDGFA, an important growth factor which causes proliferation and 
invasion of cancer cells. Moreover, we have shown that MUC1 regulates epithelial to 
mesenchymal transition during pancreatic cancer and thereby contributes to metastasis. 
Second, we have investigated the role of MUC1 in regulation of myeloid derived 
suppressor cells. We have shown that under cancer progression MUC1 regulates 
expansion and suppressive function of myeloid derived suppressor cells. Genetic 
knockout of this protein causes mice to be more susceptible to cancer growth due to 
increased myeloid derived suppressor cells function and expansion. Taken together, 
MUC1 plays a dual role in oncogenesis and cancer immunology. 
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CHAPTER 1: INTRODUCTION 
 
 
1.1 MUC1 
          Mucin 1 (designated MUC1 for human and Muc1 for mouse) is an extensively O-
glycosylated glycoprotein and the smallest member of the Mucin family. To this date, 11 
members of this family have been discovered. The secreted Mucines: MUC2, MUC5AC, 
MUC5B, MUC6, and MUC7 and the membrane tethered Mucines: MUC1,  
MUC3, MUC4, MUC11, MUC12, and MUC13 (reviewed in (Gendler 2001)). Normally, 
MUC1 is expressed on the apical surfaces of all glandular epithelial organs including 
breast, pancreas, colon, stomach, lung, salivary glands, etc as a transmembrane protein 
(Gendler 2001). Recently, MUC1 has also been detected in low levels on hematopoietic 
cells as well (Gendler 2001). The extracellular portion of MUC1 can be enzymatically 
cleaved and secreted (Peat N 1992 ; Baeckström D 1993 ) and therefore can exist in a 
soluble form in the serum and bodily fluids. (Boshell M 1992). MUC1 consists of an 
extracellular domain of variable number of tandem repeats (VNTR) of 20 amino acids 
(aa) on the amino terminal, a transmembrane domain, and a 72 aa cytoplasmic tail (CT) 
domain at the carboxyl terminal (Figure 1) (Gendler SJ 1990). Due to differential mRNA 
splicing, several MUC1 variants have been identified. MUC1 can lack either the tandem 
repeat or the cytoplasmic tail (Zrihan-Licht S. 1994; Smorodinsky N. 1996; Oosterkamp 
H. M. 1997; Baruch A. 1999) or it can exist as a heterodimer containing both the tandem 
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repeat and the cytoplasmic tail. Presence of serine and threonine hydroxyl groups 
provides the sites for O-glycosylation on the tandem repeat domain. MUC1 is referred to 
as a Polymorphic Epithelial Mucin (PEM) and depending on the extent of glycosylation 
(which accounts for 50-90% of MUC1’s weight), the molecular weight (MW) can range 
from 100 to >500 kDa. Because of extensive glycosylation and the size of the protein 
core, mature, full length MUC1 can extend from the cytoplasm up to 1500 nm and it 
resembles a bottle brush.  
 
     
 
 
Figure 1. MUC1 structure. MUC1 
contains a large extracellular 
tandem repeat domain, a short 
transmembrane domain and a small 
intracellular cytoplasmic tail. 
 
 
         In humans, MUC1 is located on the chromosome 1q21 in a closely packed region of 
the DNA (Swallow DM 1987 ). MUC1 expression is developmentally regulated and can 
be detected in the pancreas, stomach, and lung on day 12 of the gestation period (as 
reviewed in (Gendler SJ 1995)). In fact, expression of MUC1 during embryogenesis is a 
marker of epithelial differentiation. In-vivo, hormonal modulation and soluble factors 
from the connective tissue of the colon can also stimulate and regulate expression of 
MUC1 (Irimura T 1990 ).  
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          Following translation of MUC1 mRNA, the precursor of this protein is cleaved at 
the C-terminal in the Endoplasmic Reticulum (ER) into two fragments of the heterodimer 
(Ligtenberg MJ 1992). Depending on the tissue type and function of the MUC1 which 
determines the number of VNTRs, weight of MUC1 protein core ranges from 100-300 
kDa. This weight can double after the final glycosylation. MUC1 glycosylation happens 
in the ER during translation and succeeding cleavage, MUC1 is exposed to further 
glycosylation in the Golgi apparatus (Rose MC 2006). Type and extend of glycosylation 
depends on the tissue type and the organ in which MUC1 is expressed. The N-terminal of 
MUC1 contains a sequence which directs its localization to the cell membrane.  
            MUC1, an epithelial cell marker is shown to be an anti-adhesive protein (Jentoft 
1990) and can regulate epithelial morphogenesis by blocking cell-cell or cell-matrix 
interactions (Braga VM 1992 ; Hilkens J 1992 ). Expression of this protein on mucosal 
organs such as colon, can have protective function against pathogen entry, bacterial 
infection, and can regulate the host’s reaction against pathogens (McAuley JL 2007 ; 
Ueno K 2008 ; Lindén SK 2009 ) in a matrix metalloproteinase-14 (MMP-14) dependant 
manner. In the lung, due to its vast carbohydrate chains, MUC1 can bind to an array of 
bacteria, viruses, and particles that have been inhaled. Mucins in general are important 
for hydration, lubrication, and protection from proteases. Due to its long extension from 
the cell membrane, MUC1 TR can act as an environmental sensor for the cell in addition 
to ligand binding and signal transduction. MUC1 can detect changes in the pH, chemical, 
and physical conditions outside the cells. If expressed on cancer cells however, MUC1’s 
function and expression is drastically changed and its signaling mechanism is hijacked by 
the cancer cells to proliferate, metastasize, and evade death. 
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1.2 MUC1 and cancer  
          MUC1 is overexpressed and aberrantly (hypo)-glycosylated in all epithelial 
carcinomas including breast, ovarian, and pancreas as well as in some hematological 
malignancies. MUC1 overexpression on cancer cells causes increased shedding of MUC1 
in the serum. In fact, in cancers such as ovarian and breast, detection of shed MUC1 via 
standardized methods has diagnostic and prognostic potential. MUC1 is known to 
significantly contribute to oncogenesis and metastasis. During carcinogenesis, MUC1 
expression is no longer restricted to the apical surface of the cells and therefore cells lose 
their polarity. This allows MUC1 to interact with receptors which are physically 
unavailable to it under normal conditions (Figure 2). Therefore, overexpression of MUC1 
in cancer patients is correlated to both poor prognosis and increased metastasis (Fung PY 
1991 ; Kobayashi H 1992; Gendler 2001).  
 
 
       
 
 
 
Figure 2. MUC1 expression in normal and transformed 
cells. MUC1 is expressed on the apical surface of 
normal epithelial cells. However, MUC1 is over 
expressed and aberrantly glycosylated in cancer cells. 
In addition, its expression is no longer restricted to the 
apical surface. Consequently, MUC1 can interact with 
proteins and receptors which are not available to it in 
normal condition.  
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           MUC1 not only contributes to oncogenesis, but also inhibits body’s natural 
attempt to eliminate cancer cells. Expression of MUC1 on cancer cells have been shown 
to limit the killing ability of Natural Killer (NK) and Cytolytic T-cells (CTLs) (Sherblom 
AP 1986; van de Wiel-van Kemenade E 1993) and therefore help immune evasion during 
cancer progression.  
            MUC1 has a dual role in regulation of cell adhesion to the extracellular matrix. 
During oncogenesis, this anti-adhesive functions of MUC1is utilized by cancer cells to 
evade binding to extracellular matrix in order to metastasize to the distal organs.  MUC1 
can interact with Intracellular Adhesion Molecule-1 (ICAM1) on endothelial cells to 
facilitate migration of cells (Rahn JJ 2005) or it can act as an adhesive protein by 
providing ligands for selectin-like molecules (Aruffo A 1992; Majuri ML 1992) and 
assist homing of metastatic cancer cell to the new organ.            
            Hypo- glycosylation of tumor associated MUC1 results in exposure of the 
immunogenic protein core to the immune system. This makes MUC1 a compelling tumor 
antigen (Agrawal B 1998; Brossart P 1999). Pulsing Dendritic Cells (DCs) with MUC1 
peptide results in presentation of this peptide within Major Histocompatibility (MHC) 
molecules and generation of cytotoxic T-lymphocytes (CTLs) capable of lysing MUC1 
expressing tumor cells (Brossart P 1999; Tinder 2008; Mukherjee 2009). Targeting 
MUC1 as a tumor antigen either through antibodies or vaccination in hopes of preventing 
recurrence is the focus of many laboratories as well as our laboratory. Tumor associated 
MUC1 is considered to be a very promising target for immune intervention and studies 
have shown that vaccination with MUC1 peptides can result in decreased tumor burden 
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in pancreas breast and colon cancer models (Mukherjee 2004; Mukherjee 2007; 
Akporiaye ET 2007 ; Mukherjee 2009).  
            Signaling through MUC1-CT in cancer: The cytoplasmic tail of MUC1 is highly 
conserved across species and plays a major role in oncogenic signal transduction (Figure 
3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. MUC1 regulates signaling pathways which contribute to oncogenesis. MUC1-
CT can associate with SRC, FAK, and β-catenin to regulate growth, mitosis and survival 
of cancer cells. Moreover, MUC1 can associate with proteins such as β-catenin and 
translocate to the nucleus to alter transcriptional activity of transcription factors.  
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MUC1-CT contains 72 aa and resembles a cytokine receptor in its sequence with several 
tyrosines, serines, and threonines which can be subjected to phosphorylation, and 
proteolytic modification, thus affecting its interaction with other oncogenic proteins 
(Figure 4).  MUC1-CT contains 7 tyrosines which when phosphorylated associates with 
several signaling proteins to modulate signal transduction events. Members of the Src 
family such as lyn (Li Y 2003), c-Src (Al Masri A 2005), and Lck (Mukherjee P 2005) 
can phosphorylate MUC1-CT and regulate its interaction with known transcription 
factors such as β-catenin. MUC1-CT association with the Armadillo repeats on β-catenin 
through its serine rich regions stabilizes β-catenin’s translocation to the nucleus (Huang L 
2005). Furthermore, MUC1 expression is known to increase cellular levels of β-catenin in 
cancer cells through blocking Glycogen Synthase Kinase-3β (GSK3β) mediated 
destruction of β-catenin (Huang L 2005). β-catenin in the nucleus regulates 
transcriptional activity of several proteins which are responsible for regulation of c-myc 
and cyclinD. These proteins are known to be crucial for cell cycle regulation in cancer. 
Moreover, MUC1-CT is also known to translocate to the nucleus of many MUC1+ 
cancer cells and modulate transcription (Wen Y 2003; Roy, Sahraei et al. 2011; Sahraei 
2011). The exact mechanism behind MUC1-CT translocation to the nucleus is not yet 
known and to this date, no nuclear localization sequence has been found on MUC1-CT 
(Singh and Hollingsworth 2006). Therefore, MUC1-CT contributing to tumor 
progression is heavily dependent on its interactions with β-catenin and its transcriptional 
role.  
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Figure 4.  A graphic representation of the MUC1-CT. the tyrosines are shown in red. 
Known and potential interactions are indicated.  
 
            MUC1 itself is proposed to be an oncogene and its expression alone can increase 
chances of tumor formation. In fact, transfection of rat 3Y1 fibroblasts with full length 
MUC1 caused increased proliferation of these cells and injecting 3Y1-MUC1 cells to 
nude mice causes tumor formation, an event which does not happen with wild type 3Y1 
cells (Li 2003).   
             One of the biggest contributions of MUC1 to increased survival is through 
regulation of NF-κB levels and activity (Ahmad R 2007). A thorough study by Ahmad et 
al has revealed that MUC1 regulates levels of NF-κB expression as well as its nuclear 
translocation via phosphorylation and degradation of IκB. Further, MUC1-CT directly 
binds to IKKα and IKKβ to activate their complex and augments NF-κB signaling in 
response to Tumor Necrosis factor-α (TNF-α) indicating that MUC1 contributes to cell 
survival, decreased apoptosis and increased transformation via activation of the NF-κB 
pathways (Ahmad R 2007).  
           Growth factors and their signaling play a crucial role in cancer progression and 
resistance to apoptosis. MUC1-CT can interact with and get phosphorylated by growth 
factor receptors such as Epidermal Growth Factor Receptor (EGF-R) both in-vitro and in-
vivo (chroeder JA 2001; Li Y 2001; Schroeder JA 2001). Additionally, EGF-R can 
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regulate interaction of MUC1-CT with β-catenin and c-Src (Li Y 2001). This integrated 
signaling amongst MUC1-CT, EGF-R, c-Src, and GSK3β can modify c-Src/β-catenin or 
GSK3β  signaling and induces further transformation of cancer cells. 
               Another growth factor receptor which interacts with MUC1 is Fibroblast 
Growth Factor Receptor-3 (FGFR3) (Ren J 2006). FGF stimulation can increase 
MUC1/FGFR-3 association and consequently MUC1 gets phosphorylated by FGFR3 to 
increase interaction of MUC1-CT /β-catenin. Consequently β-catenin is stabilized and 
translocated to the nucleus to alter Wnt signaling and induce further oncogenesis.   
In addition to tumor progression and metastasis, MUC1 has long been associated 
with resistance to chemotherapy, stress, and apoptosis. MUC1 induces radiation 
resistance via contributing to DNA repair and indirect promotion of cell survival in 
response to DNA double strand breaks (Huang L 2010). Also, MUC1 blocks the 
genotoxic agent induced apoptosis, causing chemoresistance in cancer patients.  (Raina D 
2006). Taken together, there is mounting evidence pointing to MUC1’s direct role in 
resistance to conventional cancer treatments.  
             MUC1’s role in induction of proliferation and metastasis in some carcinomas is 
well established. Through interaction with growth factor receptors, signaling molecules 
and alteration of gene expression MUC1 plays a significant role in oncogenesis. 
Induction of proliferation, metastasis, chemo and radiation resistance, and stress 
resistance explains why MUC1 expression during cancer is associated with such bad 
prognosis. While it appears that MUC1 plays a similar role in cancers, recent findings 
point that MUC1’s contribution to oncogenesis is dependent on the nature of the tumor. 
Our laboratory investigates the role of MUC1 in pancreatic cancer progression.  
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1.3 Pancreatic cancer 
          Pancreatic Ductal Adenocarcinoma (PDA) accounts for more than 85% of all 
pancreatic cancers and is the 4th leading cause of cancer related death in the United 
Stated. Every year, 270,000 patients are globally diagnosed with this disease and the 5 
year survival rate it 5% as the patient’s quality of life decreases dramatically (Li D 
2004.). Despite significant improvements in the cancer treatment field, PDA remains to 
be one of the most challenging cancers to treat. To this date, surgical resection and early 
diagnosis are the only means by which this disease is less fatal. PDA is extremely 
resistant to chemotherapy and radiation. Early micrometastasis to distal organs is a hall 
mark of this cancer. Pancreatic cancer is not symptomatic in early stages and therefore it 
is rarely diagnosed early enough to be treated. Pancreatic cancer is highly invasive and by 
the time of diagnosis is already metastatic and therefore incurable.  
         Very little is known regarding the environmental risk factors or genetic conditions 
which cause PDA.  Some conditions such as diabetes, obesity, genetic predisposition, and 
chronic pancreatitis have been linked to PDA development. (Everhart J. 1995; C.S 2001; 
Fryzek J.P. 2001; Virtamo J. 2005). Mutations in the tumor suppressor genes such as 
BRCA2,BRCA1, INK4A, MLH1, PRSS1, and LKB1 have also been linked to development 
of PDA (Whitcomb D.C. 1996; Jaffee E.M. 2002; Thompson D. 2002). Changes in the 
pancreas environment such as pancreatitis or organ dysfunction can lead to production of 
ROS, growth factors, and inflammation which results in transformation of ductal cells 
and their unrestrained proliferation. Perhaps one of the most important mutations that 
lead to PDA development is mutations in the K-RAS oncogene. Activating mutations in 
the codon 12 of K-RAS (from G to D) replaces the asparate with glycine, or arginine, or 
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valine. These mutations are assumed to be the initiating mutations in the pancreas which 
lead to pancreatic cancer. The K-RASG12D mutation is detected in about 30% of early 
neoplasms of the PDA and 100% of advanced PDA (Almoguera C. 1988; Klimstra D.S. 
1994; Rozenblum E. 1997). Dr. Tuveson’s group has generated a mouse model which 
expresses the K-RASG12D in the ductal cells of the pancreas and has shown that this 
mutation alone can cause pancreatic cancer which progresses identical to that of humans 
(Hingorani 2003). This model is of great importance since it provides the opportunity to 
study pancreatic cancer in its natural microenvironment in immunocompetent mice with 
the proper hormonal setting.  
            In more than half of PDA specimens the tumor suppressor P53 gene has 
deactivating mutations (Rozenblum E. 1997).  Several pathways such as MAPK, 
Phosphatidilonositol-3 Kinase (PI3K), and Ral GDS become activated following the 
activating K-RASG12D mutation [as reviewed in (Campbell S.L. 1998)]. MAPK activity 
has been shown to play a significant role in proliferation of PDA cells (Hirano T. 2002; 
Gysin S. 2005). K-RASG12D mutations have been shown to regulate NF-κB transcriptional 
activity (Sclabas G.M. 2003) and NF-κB is found to be constitutively active in PDA cells 
but not normal pancreas cells (Wang W. 1999; Chandler N.M. 2004).   
           Other signaling pathways that can play a role in PDA progression are signaling 
from receptors of growth factors such as Vascular Endothelial Growth Factor (VEGF) 
(Itakura J. 1997; Seo Y. 2000), Fibroblast Growth Facrot (FGF) (Kornmann M. 1997; 
Ishiwata T. 1998), Insulin Growth Factor (IGF) (Nair P.N. 2001), EGF (Li J. 2004), and 
Hepatocyte Growth Factor (HGF) (Di Renzo M.F. 1995). Several other factors such as 
epigenetic events, telomerase shortening (Hruban R.H. 2000), Notch (Miyamoto Y. 
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2003) and Hedgehog signaling (Berman D.M. 2003; Thayer S.P. 2003) are also known to 
contribute to PDA development.  
            PDA precursor lesions are called Pancreatic Intraepithelial Neoplasia (PanIN 
lesions). Most of genetic alterations occur in these lesions. PanIN lesions have 3 grades: 
1, 2, and 3 and represent various changes which occur in a transforming pancreas. PanIN 
stages associate with accumulation of mutations in the tumor site (Feldmann 2007). 
While early and late PanIN lesions contain the K-RASG12D mutation, later stage PanINs 
contain additional mutations such as P53 and SMAD4 mutations (Wilentz RE 2000; 
Maitra A 2003).  
1.4 MUC1 expression during PDA 
            Healthy pancreas of both human (Adsay NV 2002) and mouse express MUC1 
(Peat N 1992 ). More than 90% of human PDA specimen overexpress MUC1 (Plate 
1999; Qu 2004).  Most pancreatic cancer cell lines as well as pancreatic juice of PDA 
patients express high levels of MUC1 (Batra SK 1992 ; Ho JJ 1993; Hollingsworth 1994; 
borg 2004). In pancreatic carcinomas, expression of MUC1 has been associated with 
decreased survival (Sakamoto H 1997; Utsunomiya T 1998; Hinoda Y 2003) and 
increased metastasis (Masaki Y 1999). MUC1 expression is considered to be a valuable 
prognostic and diagnostic factor for patients with PDA (Gold, Karanjawala et al. 2007; 
Grote T 2007; Westgaard, Schjolberg et al. 2009) .  
            Previous studies have reported that MUC1 expression cannot be detected in early 
PanIN lesions (Adsay NV 2002; Maitra A 2003). MUC1 glycosylation is one of the 
factors that is known to pose a problem in detection of MUC1-TR since it is known to 
mask the protein core and limit antibody access (Ho JJ 1995). Using an antibody against 
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the cytoplasmic tail of MUC1 (CT-2), we have shown that MUC1 expression can be 
detected in early stages of PDA and low grade PanIN lesions as well  suggesting MUC1 
may play a role in early development of PDA as it can be a valuable marker for initiation 
of this disease (Sahraei 2011).  
             MUC1 signaling in PDA: More than a decade ago, Satoh et al have shown that 
transfection of PDA cells (S2-013) with full-length MUC1 results in increased 
proliferation of these cells in-vitro and once injected, the resulting tumor is significantly 
larger than that of mock transfected cells (Satoh S 2000). Moreover, high numbers of 
metastatic lesions in the lung of mice injected with MUC1+ cells indicate a considerable 
function for MUC1 in increasing metastasis during PDA progression. This was the first 
report which highlighted the role of MUC1 in PDA progression. 
          MUC1’s regulation of cell adhesion plays a notable role in PDA metastasis. 
Human PDA cells are known to bind to E-selectin. MUC1 decreases the binding affinity 
of these cells to E-selectin and thereby, facilitate its detachment from extracellular matrix 
(McDermott KM 2001.). Meanwhile, PDA cells which are positive for MUC1-TR can 
aggregate with ICAM+ cells implicating that during PDA progression, MUC1-TR can 
help cancer cells detach from the basal membrane and metastasize to distal organs. Also, 
MUC1-TR can facilitate homing of PDA cell to the target organs (Kohlgraf KG 2003). 
Since early and micro metastasis is one of the major problems in PDA, MUC1’s role in 
induction of such event is of great importance.  
            MUC1 expression and β-catenin signaling during PDA: It has been shown that in 
MUC1+ PDA cells, MUC1-CT translocates to the nucleus. Moreover, MUC1 appears to 
stabilize β−catenin levels and associate with it in order to increase its nuclear localization 
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(Wen Y 2003). β-catenin/wnt signaling in PDA cells has been linked to proliferation, 
migration, and invasion (Kobayashi T 2011; Cho IR 2011). MUC1 knock down in PDA 
cells lead to release of β-catenin from the nucleus and results in increased levels of 
cytoplasmic β-catenin (Yuan Z 2007). β-catenin then forms a complex with E-cadherin 
and promotes cell adhesion which decreases cell migration and possibly lowers 
metastasis. This implies that MUC1 regulation of β-catenin signaling and nuclear 
translocation can in fact regulate metastasis. 
             In PDA cells, PDGFR-β has been shown to phosphorylate MUC1-CT at the 
HGRYVPP sequence (Singh PK 2007). Phosphorylated MUC1-CT then associates with 
β-catenin and increases its translocation to the nucleus and ultimately results in increased 
invasion of pancreatic cancer cells. Overall, there is increasing amount of evidence 
showing one of the major ways by which MUC1 regulates proliferation and invasion of 
PDA cells is through regulation of β-catenin signaling.  
            Motility, invasiveness and metastasis of cancer cells is known to be associated 
with Epithelial to Mesenchymal Transition (EMT) [as reviewed in (Nieto 2002; Thiery 
2002)]. During EMT, epithelial cells are shown to acquire fibroblastic phenotype and 
increase their motility as they loose their adherence properties. Functional loss of E-
cadherin due to Snail expression is known to be associated with this event (Batlle, 
Sancho et al. 2000; Cano, Perez-Moreno et al. 2000; Guaita, Puig et al. 2002).  In a 
thorough study by Roy LD et al, using several cell lines and in-vivo models it has been 
shown that MUC1 expression in PDA cells increases their invasiveness and that both in-
vitro and in-vivo, MUC1 expression induces EMT (Roy LD 2010). Decreased metastasis 
and increased survival of spontaneous PDA mice which lack MUC1 was also associated 
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with decreased expression of mesenchymal markers such as vimentin and increased 
expression of epithelial markers such as E-cadherin in the pancreas of these mice. Cell 
lines extracted from PDA mice which express human MUC1 (PDA.MUC1) vs. cells that 
are isolated from PDA mice which totally lack expression of Muc1 (PDA.Muc1-/-) 
express higher levels of snail, slug, N-cadherin, vimentin, and VEGF, indicating the role 
of MUC1 in regulation of the mesenchymal phenotype of PDA cells. Similar event was 
observed in human MUC1- PDA cells transfected with full length MUC1. Surprisingly, if 
MUC1-cells were transfected with a MUC1 plasmid which contained mutated tyrosines 
in the cytoplasmic tail, neither invasion nor mesenchymal markers were upregulated. 
Subcutaneous injection of these cells to nude mice resulted in increased tumor burden of 
MUC1+ cells as well as increased levels of circulating tumor cells (CTCs). Tumors 
resulted from MUC1- cells, or cells with mutated MUC1 showed both smaller tumors, 
and no CTCs were detected. Gene expression analysis revealed that MUC1 regulates 
such event at a transcriptional level. Also, MUC1 was shown to interact with β-catenin 
and translocate to the nucleus. Both their interaction and translocation was significantly 
lower in MUC1+cells which contained mutated cytoplasmic tail indicating that MUC1-
CT’s interaction with β-catenin is dependent on the tyrosines. Several studies have linked 
β-catenin transcriptional activity to EMT (von Gise, Zhou et al. 2011; Zhao, Luo et al. 
2011). Therefore, it is tempting to conclude that MUC1 regulates the EMT process by 
regulation of β-catenin nuclear localization and transcriptional activity and consequently 
induce metastasis. 
           Both β-catenin (Takahashi K 1997) and MUC1 have been shown to associate with 
EGF-R  and EGF-R has been shown to translocate to the nucleus (Wang SC 2009) and 
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induce radiation resistance (Liccardi 2011). It is possible that MUC1 is regulating nuclear 
localization of EGFR via β-catenin and by doing so modulates cell proliferation and 
sensitivity to genotoxic reagents and radiation (Wang SC 2006). Given the chemo and 
radiation resistant nature of PDA, it is appealing to blame this in part on MUC1.   
          Other MUC1 regulated PDA signaling events: Using Dr. Tuveson’s PDA model, 
our laboratory has generated spontaneous PDA mice which either express normal mouse 
Muc1 (PDA.Muc1), or human MUC1 (PDA.MUC1), or lack expression of Muc1 
(PDA.Muc1-/-) (Tinder TL 2008; Roy LD 2010; Sahraei 2011; Besmer DM 2011 ). We 
have shown a significant survival advantage in PDA.Muc1-/- mice compared to 
Muc1/MUC1 expressing PDA mice (Tinder TL 2008). Increased survival was associated 
with decreased tumor burden as well as lower metastasis in these mice.  Our studies have 
shown that pancreatic cancer in PDA.Muc1-/- mice never progressed as it did in 
PDA.Muc1 or PDA.MUC1 mice indicating a significant role for MUC1 in contributing to 
PDA progression. Decreased proliferations of MUC1-PDA cells have been speculated to 
be one of the reasons attributing to lower tumor burden. Increasing amount of support has 
been gathered which suggest MUC1 in fact regulates cell cycle arrest in PDA cells. 
MUC1+PDA cells have been shown to express higher levels of pP44/42 and Cdc-25c 
while expressing lower levels of P53 and P21 (Besmer DM 2011 ). This is in agreement 
with many other studies confirming that MUC1 induces proliferation of PDA cells. 
MUC1 siRNA treatment in PDA cells (Tsutsumida H 2006);(Yuan Z 2009; Sahraei 2011)  
decreases proliferation of these cells while transfection of MUC1- cells with MUC1 
induced increased proliferation (Sahraei 2011).  
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            Whereas many factors such as MAPK/ERK activity have been linked to 
proliferation, the upstream event which leads to their activity remains to be studied. It is 
known that many growth factors induce proliferation via MAPK/MEK. In fact, our 
studies have shown MUC1 regulates expression of Platelet-Derived Growth Factor-A 
(PDGFA), which induces proliferation in PDA cells via activation of MAPK (Sahraei 
2011). In this study, neutralization of PDGF leads to reduction of both proliferation and 
invasion to the levels of MUC1-PDA cells. MUC1 regulation of PDGFA expression was 
confirmed in in-vivo studies of both spontaneous PDA as well as injectable models of 
tumor in nude mice. On the other hand, PDGFA secretion similar to PDGFB production 
was shown to regulate β-catenin translocation to the nucleus further signifying the role of 
MUC1 in regulation of oncogenic signaling in pancreatic cancer.  
           Invasion of pancreatic cancer cells to the peripheral nerves in PDA patients is 
particularly associated with poor prognosis. This event leads to morbidity in result of 
severe incurable pain. Myelin-associated glycoprotein (MAG) is known to be expressed 
on cells of the peripheral nervous system and interact with glycoproteins. It has been 
shown that MUC1 on PDA cells interacts with MAG and binds to them (Swanson, 
McDermott et al. 2007). This can in part explain the neurotropic nature of PDA cells and 
induction of pain and morbidity.  
          MUC1 expression during PDA influences tumor microenvironment: The tumor 
microenvironment has been shown to influence functionality of infiltrated immune cells. 
Dendritic Cells (DCs) are one of the most important cells in cancer immunology. DCs are 
known to uptake tumor antigens and present them to T-cells in order to induce immune 
response. Tumor microenvironment can influence DC maturation and differentiation. As 
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mentioned, MUC1 can be cleaved from tumor cells and enter the peripheral circulation 
via draining lymph nodes. It has been suggested that shed tumor associated MUC1 can in 
fact regulate immune responses (Agrawal 1998). Monti et al have shown that when 
MUC1+ PDA cells are co-cultured with human polymorphonuclear cells, differentiation 
and maturation of DCs is affected. (Monti P 2004). This study explains that shed MUC1, 
especially sialyl-Tn glycoform interacts with mannose receptor (MR) on DCs and 
increases IL-10 production and decreases IL-12 expression in these cells and thereby 
skews their phenotype towards regulatory DCs. IL-12lowIL-10highDCs are known to 
induce T-cell anergy instead of Th1 response which is needed for anti-tumor immunity 
(Gao 1999; Jonuleit H 2001; Roncarolo MG 2001).   
            While several studies are focused on targeting MUC1 as a tumor antigen, many 
studies have shown that MUC1 expression leads to an immunosuppressive tumor 
microenvironment which causes an immense problem. Myeloid Derived Suppressor cells 
(MDSCs) and T-regulatory cells (T-regs) are known to suppress the antitumor immune 
response and allow tumor growth. We have shown that in the spontaneous model of PDA 
which expressed human MUC1, levels of both MDSCs and T-regulatory cells are higher 
within the pancreas  and that this increase is associated with higher levels of Cox2/PGE-2 
which apparently originates from MUC1+ PDA cells (Tinder 2008). Further, IDO 
activity was increased in PDA.MUC1 mice compared to PDA mice and resulted in 
decreased levels of tryptophan in the serum of these mice. This is of great importance, 
since efficient targeting of MUC1 via CTLs requires a less immunosuppressive 
microenvironment. Further studies are required to find the in-depth mechanism for such 
observation.    
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             MUC1 and angiogenesis in PDA: MMP9 and MMP2, expression in the 
pancreatic tumor have been shown to be regulated by MUC1 (Roy LD 2010). MMP9 
expression (Arnold, Mira et al. 2008; Zhang, Chen et al. 2011), as well as MMP2 
expression (Binker 2010)  have been shown to increase metastasis during PDA 
(Giannopoulos 2008). Furthermore, MUC1 has been shown to regulate transcription of 
Connective Tissue Growth Factor (CTGF) and induce its expression in pancreatic cancer 
cell lines. Behrens et al have shown that following phosphorylation of the MUC1-CT due 
to stimulation by EGF, PDGF-BB, and HGF, MUC1-CT translocates to the nucleus and 
localizes around the CTGF’s promoter and induces β-catenin and P53 mediated 
expression of CTGF (Behrens ME 2010). CTGF then induces angiogenesis and therefore 
metastasis. 
         Other studies have shown that other metastatic factors such as IL-6, IL-6R, IGF, 
VEGF,  SCF, EGF, and P-selectin are significantly higher in the tumor microenvironment 
of MUC1 expressing pancreatic cancers (Roy LD 2010). Spontaneous PDA.MUC1 mice 
have also shown significantly higher serum levels of VEGF in all stages of the disease 
(Besmer DM 2011 ). Interestingly, lack of intact MUC1-CT caused expression of these 
factors to be significantly reduced back to the levels of MUC1- PDA tumors signifying 
MUC1-CT signaling as a crucial player in induction of angiogenic tumor 
microenvironment and metastasis (Roy LD 2010).  
            Expression of PDGFA has long been associated with increased angiogenesis in 
cancer (Mantur M 2008). PDGFA is known to play a significant role in angiogenesis and 
metastasis during pancreatic cancer (Hwang RF 2003). A recent study from our lab has 
shown that MUC1 regulates PDGFA expression at the transcriptional level (Sahraei 
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2011). Moreover, we have shown that MUC1 associates with PDGFA’s transcription 
factor Hypoxia Inducible Factor-α (HIF1-α) and induces its translocation the nucleus. 
Hif1-α is well recognized for its role in angiogenesis (Coma 2011) and 
immunosuppression (Corzo 2010).  
             Targeting MUC1 in PDA: While the protein core of MUC1 in normal cells is 
masked by glycosylation (Ho JJ 1995), during cancer progression aberrant glycosylation 
allows the immunogenic protein core to be exposed. Several types of MUC1 vaccines are 
under development: peptide based, fusion based, and DNA based vaccines. The ultimate 
goal of these vaccines includes DC uptake and CTL induction which leads to memory 
formation against a tumor antigen in hopes of inhibiting cancer recurrence. Tumor 
associated MUC1 can be recognized by non-MHC restricted CTLs (Barnd 1989; 
Magarian-Blander J 1993). It has been shown that healthy human’s peripheral T-cells as 
well as bone marrow mononuclear T-cells can recognize unglycosylated MUC1 protein 
core (Noto 1997; Hiltbold EM 1998). In fact, mice with spontaneous MUC1+PDA are 
shown to have functional CTLs which recognize MUC1 and kill MUC1+ cancer cells. 
Adoptive transfer of these cells indeed resulted in rejection of MUC1+ tumor cells 
(Mukherjee 2000). This implies that shed MUC1 in the serum of PDA mice is in fact 
antigenic and can mobilize the low avidity T-cells to induce a CTL response. Further 
study revealed that vaccination with tumor cell fused DCs induced a strong anti-MUC1 
CTL response which caused a survival benefit but not decreased tumor burden 
(McConnell 2002). In mouse models, vaccination with MUC1-TR cDNA induced in 
induction of MUC1 reactive CTL and anti-MUC1 antibody response which resulted in 
both decreased tumor burden and increased survival (Rong 2009). Transfection of DCs 
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with MUC1 cDNA also elicited an anti-MUC1 immune response in patients which did 
not inhibit disease progression (Pecher 2002).  
             One of the immune evasion tactics used by PDA tumors is activated 
cyclooxygenase-2 (Cox-2) (Juuti 2006). Cox-2 is known to induce Prostaglandin E-2 
(PGE-2), a highly immunosuppressive agent. PGE-2 is known to induce and attract 
immunosuppressive cells such as MDSCs and T-regs (Ben-Baruch 2006; Muller 2006). 
Ultimately, PGE-2 downregulates CTL and T-helper lymphocyte function (Okuno 1995; 
Takayama 2002). We have shown that treatment of PDA mice with a Cox-2 inhibitor 
such as Celecoxib inhibits Cox-2 and IDO and allows peptide based MUC1 specific 
vaccine to be effective in inducing MUC1-specific CTLs and antibodies (Mukherjee 
2009). Such change was associated with decreased T-regulatory and MDSC infiltration 
within the tumor microenvironment. Eventually, Celecoxib/vaccine treated mice did not 
develop invasive PDA and had reduced tumor burden.  
            A number of clinical trials using the MUC1-TR region as the antigen have been 
described (Qu 2004; North 2005; Ramanathan, Lee et al. 2005; Loveland 2006; North 
2006; Wierecky 2006). These vaccines consist of non-glycosylated MUC1-TR peptides 
of different lengths (from 17-105 amino acids) with different carriers and adjuvants 
(diphtheria toxin, Bacillus Calmette-Guerin (BCG), mannan, keyhole limpet hemocyanin 
(KLH), DETOX, and QS-21. These clinical trials have either been ineffective or have 
reduced the progression of the disease, but did not cure/stop the PDA (Karanikas 1997; 
Adluri 1999; Gilewski 2000; Mukherjee 2000; Brossart 2001; Karanikas 2001; Salit 
2002). While immunotherapy is a promising field in cancer treatment, several obstacles 
are in the way. Tumors are very efficient in evading the anti-tumor immune response and 
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therefore even an effective anti tumor immune response might not be functional within 
the tumor microenvironment. Moreover, most of the cancer immunotherapy clinical trials 
are performed on terminal patients, or patients who are recovering from 
radiation/chemotherapy. At this stage, the immune system is considerably defected and 
cannot mount the proper immune response (Pockaj 2004; I 2009). In order to target 
MUC1 as a tumor antigen in PDA patients, it is imperative to overcome the 
immunosuppression associated with this cancer. In addition, a better pool of patients with 
less advanced disease is needed to study MUC1 targeting.  
1.5 Conclusion 
          Pancreatic cancer is a poorly understood cancer and a devastating disease with little 
promise in treatment. Radiation and chemotherapy even in combination have proven to 
be ineffective for patients. PDA is also a very painful disease due to the neurotropic 
nature of PDA cells. While expression of high levels of growth factors such as FGF, 
EGF, PDGF, IGF, VEGF and the highly metastatic nature of these cancer cells have been 
described, numerous studies have shown that MUC1 plays a significant role in regulation 
of many signaling pathways which cause PDA to be such an incurable disease. MUC1 
induces increased tumor mass during PDA while allows cancer cells to survive and resist 
chemotherapy and radiation. It also induces invasion and metastasis of this cancer 
through many signaling pathways and in so doing, explains why its expression is 
associated with such bad prognosis. MUC1 also contributes to the notorious pain that is 
associated with PDA. Overall, there is mounting amount of evidence suggesting that 
targeting MUC1 signaling might be one of the best ways to increase survival of PDA 
patients.  
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              In the cancer field, MUC1 is known as a promising tumor antigen which can 
induce a humoral response as well as being recognized by CTLs. While MUC1 can be 
targeted via antibodies and CTLs, its expression can also induce immunosuppression to 
the point that CTLs are almost ineffective within the tumor microenvironment. Studies on 
MUC1 signaling during PDA have shown that not only MUC1-TR but also MUC1-CT 
signaling must be targeted for chemotherapy/radiation and immunotherapy to be 
effective. Very few studies have been devoted to targeting MUC1-CT but due to all the 
studies on MUC1 signaling, we propose that in the future targeting MUC1-CT can be an 
effective therapeutic intervention not only for PDA, but also for other cancers which over 
express MUC1. Additionally, since MUC1 causes immune suppression, targeting MUC1-
CT may make immunological targeting of MUC1-TR to be more effective.  
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2.1 Abstract 
           Pancreatic Ductal Adenocarcinoma (PDA) has one of the worst prognoses of all 
cancers. MUC1, a transmembrane mucin glycoprotein, is a key modulator of several 
signaling pathways that affect oncogenesis, motility, and metastasis and is positively 
associated with poor prognosis in patients. However, the precise mechanism by which 
this occurs remains elusive. We report a novel association of MUC1 with Platelet-
Derived Growth Factor-A (PDGFA), one of the major drivers of tumor growth, 
angiogenesis, and metastasis in PDA. Using mouse and human PDA models, we show 
clear evidence that MUC1 regulates the expression and secretion of PDGFA and thus 
influences proliferation and invasion of pancreatic cancer cells leading to higher tumor 
burden in-vivo. In addition, we reveal that MUC1 over expressing cells are heavily 
dependent on PDGFA both for proliferation and invasion while MUC1-null cells are not, 
and that PDGFA and MUC1 are critical for translocation of β-catenin to the nucleus for 
oncogenesis to ensue. Finally, we elucidate the underlying mechanism by which MUC1 
regulates PDGFA expression and secretion in pancreatic cancer cells. We show that 
MUC1 associates with Hif1-α, a known transcription factor controlling PDGFA 
transcription and facilitates Hif1-α translocation to the nucleus. In summary, we have 
demonstrated that MUC1-induced invasion and proliferation occurs through the increased 
exogenous production of PDGFA. Thus, impeding MUC1 regulation of PDGFA 
signaling may be therapeutically beneficial for patients with PDA. 
Key words: Pancreatic Cancer, MUC1, PDGFA, β-catenin 
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2.2 Introduction 
            Pancreatic Ductal Adenocarcinoma (PDA) is the fourth leading cause of cancer 
related deaths in the United States and has one of the worst prognoses of all cancers. 
Approximately, 95% of diagnosed patients die within the first 6 months of diagnosis and 
the 5 year survival rate is <5%. PDA is naturally resistant to radiation and chemotherapy. 
Early micrometastasis to the distal organs such as lymph nodes, liver, and lung is one of 
the hallmarks of this disease (Burris HA 3rd 1997). All these features have made 
pancreatic cancer a clinically terminal disease.  
           Mucin-1 (MUC1, CD227) is a type-I transmembrane glycoprotein which is 
overexpressed and atypically glycosylated during many adenocarcinomas including PDA 
(Lan MS 1990; Baldus SE 2004). MUC1 is associated with the metastatic phenotype of 
cancer cells and in PDA, MUC1 is commonly (~70%) detected in high-grade pancreatic 
intraepithelial neoplasia (PanIN) and its expression correlates with poor prognosis 
(Chhieng, Benson et al. 2003; Levi, Klimstra et al. 2004). MUC1 has an N-terminal 
extracellular domain consisting of variable number tandem repeats (MUC1-TR) of 20 
amino acids (aa) and a C-terminal domain which includes a 53aa extracellular region, a 
transmembrane domain (TM) and a 72aa cytoplasmic tail (MUC1-CT) (Gendler, 
Lancaster et al. 1990). MUC1-CT plays a critical role in cell signaling during cancer 
progression (reviewed in (Hollingsworth MA 2004 ; Singh PK 2006 ; DD 2008 )). 
MUC1-CT has been shown to associate with β-catenin and translocate to the nucleus in 
several studies including ours and thereby influence activity of transcription factors 
(Hollingsworth MA 2004 ; Roy LD 2010). Recently, a direct contribution of MUC1 on 
invasive and metastatic properties of pancreatic cancer cell lines has been shown 
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(Kohlgraf, Gawron et al. 2003; Roy LD 2010) suggesting an important role in the 
development and progression of the disease (Adsay, Merati et al. 2002; Moniaux, 
Andrianifahanana et al. 2004; Adsay, Basturk et al. 2005). Using a spontaneous mouse 
model of PDA that expresses human MUC1, we have shown that in-vivo, MUC1 enhances 
pancreatic tumor progression and metastasis (Tinder, Subramani et al. 2008) and 
contributes to Epithelial to Mesenchymal Transition (EMT) in PDA cells (Roy LD 2010).  
             Expression of Platelet-Derived Growth Factor-A (PDGFA) and HIF1-α during 
PDA progression is associated with poor prognosis (Hoffmann AC 2008).  In addition, 
many malignancies including PDA have been associated with altered PDGF signaling 
(reviewed in (A 2004)).  Interaction of this growth factor with its receptor leads to 
cellular responses such as proliferation and migration through MEK and PI3K signaling 
respectively (A 2004). In-vivo, PDGF plays a significant role in angiogenesis and 
metastasis (reviewed in (A 2004; Mantur M 2008)). Indeed, inhibition of PDGFA 
signaling can reduce growth and metastasis of human pancreatic carcinoma (Hwang RF 
2003). Therefore, targeting PDGFA has been proposed as a adjuvant treatment in PDA 
patients (Al-Batran SE 2007). 
            In this study, we demonstrate the first evidence for MUC1 regulation of PDGFA 
during progression of PDA. Analysis using both PDA mouse models and pancreatic 
cancer cell lines revealed a significant role of MUC1 in regulation of PDGFA expression. 
We report that MUC1 increases proliferation and invasion of pancreatic cancer cells via 
regulation of PDGFA expression which is responsible for higher tumor burden and 
metastasis in MUC1-expressing PDA. Expression of MUC1 correlates with PDGFA 
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expression during PDA and for the first time we have shown the significance and 
mechanism associated with this correlation.  
2.3 Results 
MUC1 expression is detected during all stages of PDA and is correlated to PDGFA 
expression.  
          MUC1 is known to be over-expressed during PDA and leads to an aggressive 
phenotype. To evaluate the mechanism underlying MUC1 regulation of PDA 
development, we subjected RNA samples from MiaPACA-2 cells treated with MUC1 
siRNA to a Cancer Pathway RT-PCR array which profiles 84 genes representing 6 
biological pathways involved in tumorgenesis. 15 genes were significantly altered in 
MiaPACA-2 cells treated with MUC1 siRNA (Figure 1A). Of these genes, PDGFA was 
most notably down-regulated with MUC1 knockdown. Next, using samples from 
different stages of PDA in human, we studied the correlation between PDA progression, 
MUC1 expression and PDGFA expression. Our results demonstrate that MUC1 
expression is detected at early stages of the disease and increases as PanIN lesions evolve 
into adenocarcinoma (Figure 1B). In addition, we tested the same PDA specimens for 
expression of PDGFA by IHC. Our results show that although basal level expression of 
PDGFA is detectable in normal pancreas, there is a strong over-expression of PDGFA by 
dysplastic ductal cells of PDA patients in a stage dependent manner (Figure 1B).  
MUC1 regulates PDGFA expression in pancreatic cancer cell lines in vitro. 
           To study whether MUC1 regulates PDGFA expression, several pancreatic cancer 
cell lines with various levels of MUC1 expression were utilized. We used human and 
mouse cell lines that were either positive or null for MUC1. BXPC3 (MUC1low), 
 29 
Su86.86(MUC1low), MiaPACA-2(MUC1high), and Capan-1(MUC1high) as well as mouse 
cell lines KCM(MUC1high) and KCKO(MUC1null) were used. In addition, BXPC3 and 
Su86.86 that have low endogenous MUC1 were transfected with full length MUC1 or 
empty vector (Neo), while MiaPACA-2 and Capan-1 that have high endogenous MUC1 
were knocked-down for its expression with a specific siRNA. First, we show the levels of 
MUC1 using both the MUC1-TR and MUC1-CT antibodies in all of the pancreatic 
cancer cell lines. As predicted, in KCKO, BXPC3.Neo, and SU86.86.Neo cells, MUC1 
was undetectable while in KCM, BXPC3.MUC1, and SU86.86.MUC1, high expression 
of MUC1 was detected (Figure 2A). Furthermore, MiaPACA-2 and Capan-1 cells 
expressed high MUC1 while MUC1 siRNA-treated MiaPACA-2 and CAPAN-1 cells 
expressed negligible levels of MUC1 at 72 hours post siRNA treatment (Figure 2A). 
Next, protein lysates were subjected to Western blot analysis for PDGFA expression. In 
KCKO cells, expression of PDGFA was undetectable while a robust expression of 
PDGFA was noted in KCM cells (Figure 2B). Similarly, BXPC3.MUC1 cells expressed 
high levels of PDGFA while BXPC3.Neo cells expressed negligible. Moreover, in both 
of the siRNA models (MiaPACA-2 and Capan-1), expression of PDGFA was 
significantly downregulated following MUC1 siRNA treatment (Figure 2B). Thus, data 
indicate that lack of MUC1 expression in pancreatic cancer cells leads to 
absence/downregulation of PDGFA expression. In addition, introduction of MUC1 to 
pancreatic cancer cells which express very low endogenous MUC1 led to induction of 
PDGFA expression.  
To further test if MUC1-expressing cells release more PDGFA, supernatants from siRNA 
treated Capan-1, BXPC3.Neo and MUC1 and KCKO and KCM cells were analyzed for 
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presence of PDGFA using a specific ELISA. Results correlated with the PDGFA 
expression data such that Capan1, BXPC3.MUC1, and KCM cells secreted significantly 
higher levels of PDGFA compared to MUC1 siRNA treated Capan1, BXPC3.Neo, and 
KCKO cells (Figure 2C).  To this point, for the first time we have clearly shown that lack 
of MUC1 not only leads to downregulation of PDGFA expression in PDA cells but 
significantly hampers its secretion (Figure 2C).  
MUC1 regulates PDGFA expression as tumors progress in a mouse model of PDA 
and in human pancreatic tumors grown in-vivo 
            Next, we utilized our in-vivo spontaneous model of PDA to study the role of 
MUC1 in PDGFA expression and its correlation with tumor development. Tumor 
sections were H&E stained for pathological assessment and analyzed for PDGFA 
expression. In 6-week old PDA mice, pancreas architecture in all mice appeared similar 
to that of healthy C57/B6 mice. However, PDGFA expression by ductal cells appeared to 
be the highest in PDA.MUC1 mice and lowest in PDA.Muc1-/- mice (Figure 2Di, ii). In 
6-month old mice, at which time, PanIN  lesions become evident (Hingorani 2003), 
expression of PDGFA was lowest in PDA.Muc1-/- mice and correlated with presence of 
small numbers of low grade PanIN lesions. However, pancreas from both PDA and 
PDA.MUC1 mice showed stronger expression of PDGFA with higher numbers of PanIN 
lesions and disruption of pancreas’s architecture (Figure 2D iii).  Finally, in 8- month old 
PDA.Muc1-/- mice, pancreas sections showed the presence of PanIN-1A lesions as well 
as low numbers of late stage PanIN lesions which correlated with low expression of 
PDGFA.  However, at the same age, pancreas from PDA mice showed higher numbers of 
late stage PanIN lesions and higher PDGFA expression. Importantly, pancreas from 
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PDA.MUC1 mice showed the highest numbers of late stage PanIN lesions and 
adenocarcinoma which correlated with strongest expression of PDGFA (Figure 2D iv). 
Similarly, IHC of tumors derived from human pancreatic cancer cell lines, 
BXPC3.MUC1 established in vivo in nude mice showed high in situ levels of PDGFA 
while none was detectable in the BXPC3.Neo tumors (Figure 2D v). Taken together, data 
shows a strong link between MUC1 and PDGFA expression during tumor progression in 
vivo.  
MUC1-expressing PDA cells have increased tumor growth in-vivo and higher 
proliferative and invasive potential in-vitro as compared to Muc1-null PDA cells 
            To determine if higher MUC1 and PDGFA expression translate to increased 
tumor growth in-vivo, two autochthonous models using mouse and human cell lines were 
used. C57/B6 mice were injected with KCKO and KCM cells and tumor weight was 
monitored and assessed at sacrifice. Tumors resulting from KCM cells were significantly 
larger than KCKO tumors (Figure 3Ai). Similarly, BXPC3.Neo and BxPC3.MUC1 cells 
were injected into nude mice and tumor weight measured. tumors resulting from 
BXPC3.MUC1 cells was significantly larger than that of BXPC3.Neo (Figure 3A ii) 
confirming the results of our previously published studies in the spontaneous model of 
PDA (Roy LD 2010).  Thus, data provides strong evidence that tumor cells expressing 
MUC1 have a significant growth advantage compared to tumors that are null for MUC1 
and this is most likely due to the role of MUC1 in regulating PDGFA which increases 
cell proliferation.  Indeed, using thymidine (3H) uptake assay, we clearly demonstrate that 
cells expressing MUC1 have significantly higher proliferation when compared to cells 
lacking MUC1. This was observed in KCM versus KCKO; BXPC3.Neo versus 
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BXPC3.MUC1; MiaPACA-2 versus siRNA-treated MiaPACA-2 and Capan-1 versus 
siRNA-treated Capan-1 cells (Figure 3Bi-iv).  
Since PDGFA is also a known inducer of invasion, pancreatic cancer cell lines were 
subjected to the in-vitro Boyden chamber invasion assay. Results demonstrate that 
invasion of KCKO and BXPC3.Neo cells through the growth factor reduced matrigel was 
significantly lower than that of KCM and BXPC3.MUC1cells respectively (Figure 3C i 
and ii). Similarly, both MiaPACA-2 and Capan-1 show decreased invasion following 72 
hours of MUC1 siRNA treatment (Figure 3C iii and iv). (Note: all p values are provided 
in the figure legend). Taken together, data presents strong evidence for the significant 
function of MUC1 in augmenting proliferation and the invasive properties of pancreatic 
cancer cells. 
 PDGFA expression by pancreatic cancer cell lines contributes to increased invasion 
and proliferation of these cells. 
            To this point, we have shown that high MUC1 levels in tumors correlate with 
high PDGFA levels leading to increased tumor burden. Therefore, to elucidate if the 
higher proliferation in MUC1-expressing cells is indeed due to regulation of PDGFA, we 
neutralized PDGFA with a specific antibody prior to subjecting the tumor cells to a 3H-
thymidine proliferation assay. We presume that neutralizing PDGFA will inhibit its 
interaction with the receptor. Proliferation of KCM cells was significantly reduced 
following PDGFA neutralization; however, proliferation of KCKO cells remained 
unchanged (Figure 4Ai). The same phenomenon was observed in BXPC3 cells. Once 
PDGFA was neutralized in the supernatant of these cells, BXPC3.MUC1 showed 
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significantly less proliferation while proliferation of BXPC3.Neo cells remained 
unchanged (Figure 4Bii).  
            Similarly, PDGFA neutralization significantly reduced the invasive index of 
MUC1-expressing tumor cells including KCM, BxPC3.MUC1, and MiaPACA-2 cells but 
not so in KCKO, BXPC3.Neo, and MUC1 siRNA-treated MiaPACA-2 cells (Figure 4Bi-
iii). Of note is that there was no difference in the levels of PDGF-Rα, which is the 
receptor responsible for PDGFA binding between the MUC1-negative and MUC1-
positive cells (data not shown). Taken together, our data shows that cells lacking MUC1 
not only produce less PDGFA but are also not dependent on PDGFA, a possible 
explanation for low growth and metastatic potential of MUC1-negative cancer cells.  
MUC1 associates with Hif-1α  and regulates its translocation to the nucleus.  
             To further elucidate the underlying mechanism, since HIF-1α is a transcription 
factor known to regulate PDGF-A production and is also associated with poor prognosis 
during PDA (Moon JO 2009) (Hoffmann AC 2008; Hoffmann AC 2008; Reiser-Erkan C 
2008), we hypothesized that MUC1 regulates translocation of this protein to the nucleus 
and thus its activation in pancreatic cancer cell lines. Therefore, we first examined the 
interaction between HIF-1α and MUC1-CT in pancreatic cancer cell lines by co-
immunoprecipitation assays. Results show that in all MUC1 expressing pancreatic cancer 
cell lines, Hif-1α associates with MUC1-CT (Figure 5A). This was validated using two 
different clones of Hif-1α antibody (data not shown). Next, we tested the effects of the 
interaction on Hif-1α nuclear translocation. Nuclear extracts of KCKO/KCM, BXPC3 
and SU86.86 cells were subjected to Western blot for presence of Hif-1α. We show that 
KCM cells have higher levels of Hif-1α translocation to the nucleus compared to KCKO 
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cells (Figure 5Bi). Further, BXPC3 and SU86.86 cells transfected with MUC1 plasmid 
show translocation of Hif-1α to their nucleus while BXPC3.Neo and SU86.86.Neo cells 
show no detectable levels of Hif-1α in their nucleus (Figure 5Bii). To validate the role of 
Hif1-α in regulation of PDGFA, BXPC3.Neo and MUC1 cells were treated with a Hif1-
α inhibitor for 24hours. Protein lysates were then subjected to Western blot for presence 
of PDGFA. Our results show that following HIF1-α inhibition, expression of PDGFA is 
strongly downregulated in BXPC3.MUC1 cells (Figure 5C). This suggests that regulation 
of PDGFA via MUC1 may require translocation of Hif-1α to the nucleus which is known 
to affect PDGFA expression.  
MUC1 associates with β-catenin and translocates to the nucleus 
         PDGFA and MUC1 have both been shown to induce translocation of β-catenin to 
the nucleus and promotion of tumor genesis and EMT (Huang L 2003 ; Leng Y 2007; 
Fischer AN 2007 ; Hattrup CL 2008; Singh PK 2008; Roy LD 2010).  Therefore, to study 
MUC1-CT association with β-catenin and its translocation to the nucleus, first, using 
several cell lines, we show that MUC1 and β-catenin associate with each other in all of 
the MUC1-positive pancreatic cancer cell lines tested (Figure 5D); second, we 
demonstrate that MUC1-CT translocates to the nucleus of all MUC1-positive pancreatic 
cancer cell lines that were analyzed (Figure 5D). Similarly, although low level 
translocation of β-catenin was observed in KCKO, BXPC3, and SU86.86 cells, the levels 
were significantly higher in KCM, BXPC3.MUC1, and SU86.86.MUC1 cells (Figure 
5E).   
Studies have shown that PDGFA regulates β-catenin translocation to the nucleus of liver 
cancer cells (Fischer AN 2007 ), therefore, we hypothesized that translocation of β-
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catenin to the nucleus of pancreatic cancer cells is dependent on PDGFA secretion. 
Therefore, we treated BXPC3.Neo and MUC1 cells with recombinant PDGFAA, or 
neutralizing PDGFA antibody and studied translocation of β-catenin to the nucleus of 
these cells. Result clearly demonstrates that treatment with exogenous PDGFAA 
increases translocation of β-catenin to the nucleus in the BXPC3.Neo cells which 
normally do not express MUC1 and have very low levels of β-catenin in the nucleus 
(Figure 5F). In addition, neutralizing PDGFA in the supernatant of BXPC3.MUC1 cells 
resulted in decreased translocation of β-catenin to the nucleus (Figure 5F). Taken all 
together, we have shown that MUC1 regulation of β-catenin translocation to the nucleus 
is in part dependent on PDGFA.  
2.4 Discussion 
          To this date, PDA is one of the most challenging cancers. It is a highly metastatic 
tumor and greatly resistant to chemotherapy. While MUC1 has been proposed as a 
marker for pancreatic cancer detection (Szajda SD 2011 ), its significant role in PDA 
development has not been fully explored.  Data from this study shows that MUC1 
enhances pancreatic tumor progression and invasiveness by directly regulating the levels 
of PDGFA expression and secretion. PDGFA expression during pancreatic cancer 
correlates with poor prognosis and is proposed to be a potential drug target for pancreatic 
cancer treatment (Al-Batran SE 2007). Similarly, MUC1 has also been implicated as a 
marker for poor prognosis and a target for therapeutic intervention in pancreatic cancer 
(Szajda SD 2011 ). This is the first study to show a direct relationship between these two 
pancreatic tumor promoting factors. The evidence for this association is overwhelming as 
we have shown that MUC1 over expression induces PDGFA in multiple human and 
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mouse cell lines in-vitro and in-vivo as well as in models of PDA that either express 
MUC1 or are Muc1-null (Figure 1-2).   
            Since MUC1 antibodies against the tandem repeat are sensitive to the pattern of 
glycosylation, detection of MUC1 on early stage human PDA samples is challenging. In 
this study, using antibody against MUC1-CT we have shown that MUC1 is 
overexpressed in all stages of pancreatic cancer (Figure 1). The first evidence that lack of 
MUC1 in PDA cells indeed down regulates PDGFA expression came from the Human 
Cancer Pathway RT-PCR assay (Figure 1A) and in fact, we have shown a strong 
correlation between expression of these two proteins in human PDA samples at different 
stages (Figure 1B). We report that MUC1-over expressing PDA cells and tumors express 
and secrete higher levels of PDGFA which accounts for the increased proliferative and 
invasive index of these cells as compared to PDA cells and tumors that lack MUC1 and 
therefore have lower levels of PDGFA (Figure 3). Of additional significance is that PDA 
mice lacking Muc1 (PDA.Muc1-/- mice) have low levels of PDGFA expression 
correlating with low-grade PanIN lesions that do not progress to invasive disease versus 
PDA.MUC1 mice that have high PDGFA expression with high-grade PanINs that do 
progress to invasive adenocarcinoma (Figure 2D).  
            PDGFA has long been associated with cancer progression (reviewed in (A 2004)) 
and can increase proliferation and invasion through the MEK and PI3K pathway 
respectively (as reviewed in (Heldin CH 1998 ; Castaneda CA 2010 )) and 2). Thus, we 
propose for the first time that MUC1 modulates pancreatic cancer growth and progression 
via inducing expression and secretion of PDGFA. Our PDGFA neutralizing study 
demonstrates the significant role of PDGFA in induction of proliferation and invasion of 
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pancreatic cancer cells (Figure 4). HIF1-α expression during PDA is correlated to 
PDGFA expression and poor prognosis (Hoffmann AC 2008; Hoffmann AC 2008), 
therefore we hypothesized that MUC1 association with Hif1-α leads to increased 
translocation of this transcription factor which is a known regulator of PDGFA induction 
(Moon JO 2009) and that is exactly what we report (Figure 5). Although Hif-1α 
expression is very low during normaxia, we were able to detect its association with 
MUC1-CT using two different antibodies against Hif-1α. In fact, we show that inhibition 
of Hif1-α leads to significant decrease in the levels of PDGFA expression (Figure 5). 
These results provide us with in-direct evidence that MUC1 up regulates PDGFA 
expression via up regulation of HIF-1α translocation to the nucleus. MUC1 is a known 
regulator of transcription, and several studies including a recent study has shown that 
MUC1 translocation to the nucleus can alter expression of growth factors and therefore 
influence the tumor microenvironment (Behrens ME 2010).   
           Further, the association of MUC1-CT with β-catenin and translocation of the 
complex to the nucleus (Figure 5C-D) is critical for oncogenesis. It is of significance that 
translocation of β-catenin to the nucleus is strongly dependent on MUC1 levels such that 
if cells do not have MUC1, very little β-catenin is found in the nucleus (Figure 5) 
although there is abundant β-catenin in the whole cell lysates.  Previous data have shown 
the strong role of PDGFA in nuclear localization of β-catenin during liver cancer (Fischer 
AN 2007 ). Also, other studies have pointed the role of PDGFB in nuclear translocation 
of β-catenin in pancreatic cancer (Singh PK 2007). In this study, through neutralizing 
PDGFA, we have shown that translocation of β-catenin is decreased even if cells express 
high levels of MUC1. In addition, we have shown that via adding PDGFAA to MUC1-
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negative cells, β-catenin localizes to the nucleus (Figure 5F). Therefore, we report that 
MUC1 regulation of PDGFA has an additive effect on β-catenin translocation to the 
nucleus, which can consequently alter EMT, metastasis, and cancer stem cell production 
as reviewed in (Singh A 2010 ) and schematically illustrated in Figure 6. 
            While MUC1-TR is proposed to be a targetable tumor antigen during PDA, 
growing evidence implicate the significant role of MUC1-CT in tumor progression. 
Moreover, clinical trials targeting PDGFA alone have shown limited success, therefore, 
targeting MUC1 signaling may be an alternative strategy that warrants further 
investigation. It is also plausible that MUC1 expression may be used as a surrogate 
biomarker for aggressive pancreatic tumors that over-express PDGFA.  
2.5 Materials and methods 
Cell lines  
           BXPC3 and SU86.86, MiaPACA-2, and Capan-1 (American Type Culture 
Collection (ATCC), Manassas, VA) were maintained in RPMI and DMEM (Invitrogen, 
Carlsbad, CA), 10%FCS, 1%penicillin/streptomycin and 1%glutamax (Invitrogen). 
KCM/KCKO, generated from tumors derived from PDA×MUC1.Tg mice and 
PDA×Muc1KO mice respectively (Roy LD 2010), and  were maintained in DMEM . All 
cell types were maintained in 5% CO2 and 95% humidity.  
RT-PCR Microarray  
             MiaPACA-2 cells were treated with MUC1 siRNA or scramble siRNA for 72 
hours. RNA isolation was performed using RNAeasy Mini Kit (QIAGEN Sciences, 
Valencia, CA) according to the manufacturer’s protocol.  cDNA was constructed from 
RNA using TaqMan cDNA kit from Applied Bioscience (Foster City, CA) and subjected 
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to real-time PCR Cancer PathwayFinder PCR Array (SABiosciences, MD). Arrays were 
performed independently at least three times for each treatment. Only genes showing 
consistent alteration with both controls were included in the results reported here. The 
reaction was carried using ABIPRISM7900HT thermocycler. Data were analyzed using 
SABiosciences software.  
Human samples  
           Tissue sections of normal pancreas and PDA was acquired from the NIH/NCI 
tissue repository (http://seer.cancer.gov/biospecimen).  
Immunohistochemistry  
           Tumor sections were formalin-fixed, Paraffin-embedded, and sectioned. PDGFA 
expression was determined using the Santa Cruz Biotechnologies antibodies followed by 
the appropriate secondary antibody ( DAKO, Carpenteria, CA). Sections were developed 
using 3,3”–Diaminobenzidine as the chromogen and hematoxylin was used as the 
counterstain. pictures were taken at 40X magnification. Hematoxylin/Eosin (H&E) 
staining was performed using a standard protocol. 
Cloning of MUC1 vectors 
            BXPC3 and SU86.86 are PDA cell lines that express low to no endogenous 
MUC1. For retroviral infection, GP2-293 packaging cells were co-transfected with the 
full-length MUC1 construct or empty vector expressing the neomycin resistance gene and 
VSV-G envelope protein as previously described (Thompson, Shanmugam et al. 2006). 
Virus was subsequently pelleted, resuspended in medium containing 8 µg/mL polybrene 
and incubated overnight with PDA cells that had been pretreated for 2-3 hours with 
polybrene. Cells were selected with 0.5 mg/mL G418 for 48 hours post infection and were 
 40 
maintained as polyclonal populations until sorted for MUC1-positive and negative cells. 
Two independent infections of the constructs were carried out with similar results. 
Expression of the constructs was stable throughout the span of experiments. Cells infected 
with vector alone were used as control and designated as ‘Neo’. For MUC1 cells, 
MUC1+ve cells were sorted using the FACSAria. For Neo-infected cells, MUC1-ve cells 
were sorted. Level of MUC1 expression was validated using Western blot analysis 
(Figure 2A) and Flow cytometry (data not shown).  
MUC1 knockdown: 
             MiaPACA-2 and Capan-1 cells were seeded in 6 well plates and at 30% 
confluency were treated with 100nM siGENOME SMART pool siRNA targeting MUC1 
or 100nM of scramble siRNA as control (DHARMACON, Thermo Fisher Sc.). siRNA 
was incubated with cells in presence of Lipofectamine (Invitrogen) for 5-6 hours in 
serum-free Opti-MEM (Invitrogen). Cells were then washed with PBS and FBS 
containing DMEM was added. Levels of MUC1 expression were checked 48, 72, and 96 
hours post siRNA treatment.  
PDGFA ELISA 
            Supernatants from PDA cells were collected. The levels of PDGFA secretion was 
analyzed using Human/Mouse PDGF-AA Immunoassay (R and D systems, MN) 
according to the manufacturer’s protocol. 
Mouse Model 
              PDA mice were generated in our laboratory congenic on the C57BL/6 
background by mating the P48-Cre with the LSL-KRASG12D mice (Hingorani 2003; Roy 
LD 2010) to produce PDA mice and further mated to the human MUC1.Tg mice to 
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generate PDA.MUC1 mice (Tinder, Subramani et al. 2008; Mukherjee, Basu et al. 2009) 
or to the Muc1-/- mice (Spicer, Rowse et al. 1995) to generate PDA.Muc1-/- mice. Primary 
tumors were dissociated using collagenase-IV and several lines of cells were generated in 
our laboratory. These cells are designated KCKO for PDA cells lacking Muc1 and KCM 
for PDA cells expressing human MUC1. Thus far, we have been unable to make cell 
lines from PDA mice.  PDA mice were sacrificed at 6 weeks (pre-neoplastic), 15 weeks 
(PanIN-1A), 26 weeks (PanIN-1A), and 40 weeks (PanIN-1A,B, PanIN-2, and PanIN-3) 
of age (Hingorani 2003). Part of the tumor tissue was fixed in formalin for future IHC. 
Proliferation: 
           Cells were serum starved for 24 hours prior the assay. 5000 cells were seeded in 
96 well plates and were incubated with 1µCu 3H-thymidine (PerkinElmer, Waltham, 
MA). 24 hours later, 3H-thymidine uptake was measured using TopCount micro-
scintillation counter (PerkinElmer).  
In-vivo tumor growth  
             For BXPC3 tumors, two-month old nude mice (Jackson Laboratory, Bar Harbor, 
ME) were subcutaneously (s.c.) injected with 5x106 BXPC3.MUC1 or BXPC3.Neo cells 
into the flank of the mice. Tumors were allowed to grow for two months. For 
KCKO/KCM tumors, three-month old male C57/B6 mice were injected with 1X106 
KCKO or KCM cells s.c. in the flank. Tumors were allowed to grow for 18 days. Upon 
sacrifice, tumor weight was measured and part of the tumor tissue was fixed in formalin 
for future IHC.   
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Invasion Assay:  
             Serum starved cells (30,000 cells) were plated over trans-well inserts (BD 
Biosciences, Sparks, MD) pre-coated with growth-factor reduced matrigel (BD 
Biosciences) and were permitted to invade towards serum-contained in the bottom 
chamber for 48 hours. Non-invaded cells were swabbed from the tops of half of the 
inserts ('samples', containing only invaded cells), and retained in the others ('controls', all 
cells). Inserts were stained for 10 minutes with crystal-violet (0.5% in 20% methanol) 
and washed with water. Membranes were destained in 10% acetic acid and absorbance 
read at 570nm (Single Plate Reader, Molecular Devices, Sunnyvale, CA). Percent 
invasion was calculated as absorbance of samples/absorbance of controls×100.  
PDGFA neutralization, Hif1-α  inhibition, and PDGFA treatment:  
             PDGF neutralization was performed using anti-PDGFA neutralizing antibody 
(Millipore, Billerica, MA) according to the company’s instructions. Cells were cultured 
in 6 well plates and 24 hours post culture, 1 ml of supernatant was treated with 20µg of 
neutralizing antibody for 1 hour at 37ºC. Cells were then subjected to either a 
proliferation or invasion assay. Hif1-α inhibition studies were done by treating cells with 
Hif1-α inhibitor (Santa Cruz Biotechnology). Cells were treated with 30 µM of Hif1-α 
inhibitor for 24 hours and then subjected to Western blot analysis. PDGFA treatment was 
performed by addition of 50ng/ml of rPDGF-AA (Peprotech, Rocky Hill, NJ) for 4 hours. 
Western Blots and Antibodies 
            Briefly, cells were lysed in HEPES buffer (20mmol/L HEPES, 150mmol/L NaCl, 
1%Triton X-100, 2mmol/L EDTA) containing protease (Complete inhibitor cocktail; 
Roche, Indianapolis, IN) and phosphatase inhibitors (Sigma). Equal quantities of lysate 
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were loaded on SDS-PAGE gels. MUC1-CT antibody CT2, was made in Mayo Clinic 
Immunology Core (chroeder JA 2001).  MUC1-TR antibody (HMFG-2) was acquired as 
a kind gift from Prof. Joyce Taylor-Papadimitriou (King's College London School of 
Medicine, Guy's Hospital, London UK). All other antibodies (β-actin, PDGFA, β-catenin, 
Hif-1α (clones H26 and C19), Lamin-B, and IKK) (Santa Cruz Biotechnology) were used 
according to manufacturer's recommendations. Co-immunoprecipitation (co-IP) using 
CT2 and β-catenin were carried out as previously reported  (Al Masri and Gendler 2005) 
using 1mg of protein lysate prepared in 1% Brij buffer (Sigma) followed by standard 
western blotting. 
Sub-cellular fractionation  
             Cells were resuspended in buffer-A (10mM HEPES pH7.5, 10mM KCl, 0.1mM 
EDTA, 0.1mM EGTA and 0.1%Nonidet-P40) on ice. Lysate was spun at 6000 rpm, 
2min, 4°C and the resulting pellet was washed twice in 1x ice-cold PBS before sonication 
in buffer-B (20mM HEPES ph7.9, 25%glycerol, 400mM NaCl, 1.5mM MgCl2, 0.2mM 
EDTA, 0.5mM DTT) to obtain the nuclear fraction which was then spun at 13000 rpm 
for 10min, 4°C, for western blot analysis using MUC1-CT, β-catenin, and Hif-1α 
antibodies.  
Statistical analysis 
          Statistical analysis was performed with GraphPad software. P-values were 
generated using the one way Anova and significance was confirmed using the Duncan 
and Student-Newman-Keul test. Values were considered significant if p < 0.05. 
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2.6 Figures 
 
 
Figure 1. MUC1 overexpression is detected in all stages of PDA and is correlated to 
increased expression of PDGFA. A) Fold change in mRNA levels in WT versus 
MUC1siRNA-treated MiaPACA-2 cells. Differences over 2-fold are shown (n=3, 
p<0.05). B) H&E staining and detection of MUC1 and PDGFA over expression during 
all stages of human PDA. MUC1 is detected using antibody specific to the cytoplasmic 
tail.  
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Figure 2. MUC1 regulates PDGFA expression during pancreatic cancer. A) Western blot 
analysis of MUC1 expression in human and mouse pancreatic cancer cell lines using both 
the MUC1 TR and MUC1 CT-specific antibodies. Additionally, downregulation of 
MUC1 expression in MiaPACA-2 and Capan-1 cells 72 hours post siRNA treatment. 
Representative blots from 3 separate experiments are shown. B) Western blotting analysis 
of PDGFA expression in various pancreatic cancer cell lines. C) Levels of PDGF-A 
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secreted in the supernatant of WT and MUC1 or control siRNA-treated Capan-1, 
BXPC3.Neo/MUC1, and KCKO/KCM cells as measured by specific ELISA (n=4) 
(***P<0.0001, *P<0.05). D) i-iv: Histology and corresponding PDGF-A expression in 
pancreas of PDA.Muc1-/-, PDA, and PDA.MUC1 mice at 6-weeks (ii), 6-months (iii) and 
8-months (iv) of age (n=5). Representative images from normal 6-month old C57BL/6 
pancreas is shown as control. v: PDGFA expression in BXPC3.neo and MUC1 tumors 
from nude mice. Images are captured at 40X magnification.  
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Figure 3. MUC1 regulates tumor burden, proliferation, and invasion of pancreatic cancer 
cell lines. B) Proliferation of MUC1+ and MUC1- pancreatic cancer cells as measured by 
3H-thymidine uptake (cpms) (n=4) (*P<0.05, **P<0.01). A i and ii) Tumor wet weight of 
KCKO versus KCM (i) and BxPC3.Neo versus BxPC3.MUC1 tumors in vivo. 1x106 
KCKO or KCM cells were injected in the flank of C57BL/6 mice and tumor wet weight 
measured 18-days post tumor cell inoculation (n=5) (**P<0.01) whereas 5x106 
BXPC3.Neo or BXPC3.MUC1 cells were injected in the flank of nude mice and tumor 
wet weight taken 60-days post tumor cell inoculation (n=3) (**P<0.01). C) Percent cells 
that invaded through growth factor-reduced matrigel in a Boyden chamber invasion assay 
(n=4) (***P=0.001, *P=0.05).  
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Figure 4. PDGF regulates invasion and proliferation of MUC1+ pancreatic cancer cells 
but has no effect on MUC1- cells A) Proliferation of pancreatic cancer cells as measured 
by 3H-thymidine uptake (cpms) following PDGF neutralization (n=4) (*P<0.05, and 
***P=0.001). B) Percent cells that invade through growth factor-reduced matrigel 
following PDGF neutralization. (n=3), (*P< 0.05 and ***P=0.001). 
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Figure 5. MUC1 interacts with HIF-1α and β-catenin. Nuclear translocation of MUC1, β-
catenin and HIF-1α: A) Co-IP of MUC1-CT and HIF-1α in several cell lines 
demonstrating the interaction of MUC1-CT and HIF-1α. B) HIF-1α translocation to the 
nucleus of i) KCKO and KCM mouse PDA cells; and ii) Su86.86 and BxPC3 human 
cells. More HIF-1α in MUC1-expressing versus MUC1 null pancreatic cancer cells. 
Lamin B and IKK serve as positive and negative markers for nuclear extracts. C) Western 
blot analysis for expression of PDGFA in BXPC3.Neo and MUC1 cells treated with 
30µM Hif1-α inhibitor for 24hours. D) Co-IP of MUC1 CT and β-catenin in both 
directions in cell lines demonstrates the binding of these two proteins. E) Translocation of 
MUC1-CT and β-catenin to the nucleus i) KCKO, KCM, Su86.86, and BxPC3 cells 
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indicating the activation of β-catenin as a transcription factor; ii) MUC1-CT detected in 
high levels in the nucleus of Capan-1 and MiaPACA-2 cells. F) Western blot analysis for 
presence of β-catenin in the nucleus in BXPC3.Neo and MUC1 cells treated with either 
50ng/ml of rPDGFA, or 20µg of PDGFA neutralizing antibody for 24 hours. Lamin B 
and IKK serve as positive and negative markers for nuclear extracts. 
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Figure 6. Schematic of the possible mechanism underlying MUC1 regulation of PDGFA. 
In MUC1 positive PDA cells, MUC1-CT associates with HIF1-α and facilitates its 
translocation to the nucleus. This results in expression of PDGFA which is then secreted 
and interacts with PDGFR-α. Signaling through PDGFR-α has an additive effect on β-
catenin translocation and enhances proliferation and metastasis.  
CHAPTER 3: MUC1 AND EMT 
 
 
MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to 
mesenchymal transition 
Lopamudra D. Roy, Mahnaz, M. Sahraei, Durai B. Subramani, Dahlia Besmer, 
Sritama Nath, Teresa L. Tinder, Kandavel Shanmugam, Ekta Bajaj, Sandra J. 
Gendler, and Pinku Mukherjee* 
3.1 Abstract 
           Increased motility and invasiveness of pancreatic cancer cells are associated with 
epithelial to mesenchymal transition (EMT). Snai1 and Slug are zinc-finger transcription 
factors that trigger this process by repressing E-cadherin and enhancing vimentin and N-
Cadherin protein expression. However, the mechanisms that regulate this activation in 
pancreatic tumors remain elusive. MUC1, a transmembrane mucin glycoprotein, is 
associated with the most invasive forms of pancreatic adenocarcinomas (PDA). In this 
study, we show that over expression of MUC1 in pancreatic cancer cells trigger the 
molecular process of EMT which translates to increased invasiveness and metastasis. 
EMT was significantly reduced when Muc1 was genetically deleted in a mouse model of 
PDA or when all seven tyrosines in the cytoplasmic tail of MUC1 were mutated to 
phenylalanine (mutated MUC1 CT). Using proteomics, RT-PCR, and western blotting, 
we revealed a significant increase in vimentin, N-Cadherin, Slug and Snai1 expression 
with repression of E-Cadherin in MUC1-expressing cells compared to cells expressing 
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the mutated MUC1 CT. In the cells that carried the mutated MUC1 CT, MUC1 failed to 
co-immunoprecipitate with β-catenin and translocate to the nucleus thereby blocking 
transcription of the genes associated with EMT and metastasis. Thus, functional tyrosines 
are critical in stimulating the interactions between MUC1 and β-catenin and their nuclear 
translocation to initiate the process of EMT. This study signifies the oncogenic role of 
MUC1 CT and is the first to identify a direct role of the MUC1 in initiating EMT during 
pancreatic cancer. The data may have implications in future design of MUC1-targeted 
therapies for pancreatic cancer.  
3.2 Introduction 
Pancreatic Ductal Adenocarcinoma (PDA) is the fourth leading cause of cancer 
death in the United States (Saif 2006). This disease remains a major therapeutic 
challenge, as it is naturally resistant to current chemotherapy/radiation therapies. Poor 
prognosis has been attributed to delayed diagnosis and early vascular dissemination, 
spread to regional lymph nodes, and metastases to distant organs, especially the liver and 
peritoneum (Burris, Moore et al. 1997). One important insight came from the discovery 
that the increased motility and invasiveness of cancer cells are associated with EMT 
(Nieto 2002; Thiery 2002). In EMT, epithelial cells acquire fibroblast-like properties and 
show reduced intercellular adhesion and increased motility. This process is associated 
with the transcriptional repression and functional loss of E-cadherin (Nieto 2002; Thiery 
2002). Several transcription factors have been implicated in this repression, including the 
zinc-finger proteins of the Snai1/Slug family (Batlle, Sancho et al. 2000; Cano, Perez-
Moreno et al. 2000; Guaita, Puig et al. 2002), δEF1/ZEB1, SIP1 (Comijn, Berx et al. 
2001), and the basic helix-loop-helix E12/E47 factor (Bolos, Peinado et al. 2003). Snai1 
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was shown to repress the expression of E-cadherin and induce EMT in several cancer 
cells (Batlle, Sancho et al. 2000; Cano, Perez-Moreno et al. 2000; Guaita, Puig et al. 
2002). Although several factors such as TGF-β and the estrogen receptor were shown to 
regulate Snail transcription (Fujita, Jaye et al. 2003; Peinado, Quintanilla et al. 2003), the 
mechanisms that modulate the function of Snail have remained largely elusive. Recently, 
dual regulation of Snai1 by GSK-3β-mediated phosphorylation has been implicated in 
EMT (Zhou, Deng et al. 2004). 
           MUC1 is a transmembrane mucin glycoprotein that is over-expressed and 
aberrantly glycosylated in 100% of metastatic PDA (Lan, Batra et al. 1990). Although 
elevated levels of MUC1 protein have been associated with higher metastasis and poor 
prognosis, its molecular role in metastasis remain unclear (Patton, Gendler et al. 1995; 
Spicer, Rowse et al. 1995; Schroeder, Adriance et al. 2003; Tinder, Subramani et al. 
2008). Multiple reports have appeared over the past decade demonstrating an incredible 
range of intracellular signaling functions associated with the 72–amino acid residue of 
MUC1 CT which is reviewed in (Hollingsworth and Swanson 2004; Singh and 
Hollingsworth 2006; Carson 2008). MUC1 CT is a target for several kinases, including ζ 
chain–associated protein kinase of 70 kD (ZAP-70), the δ  isoform of protein kinase C 
(PKCδ), glycogen synthase kinase-3β (GSK-3β), and the tyrosine kinases c-Src and Lck 
(Mukherjee, Tinder et al. 2005; Hattrup and Gendler 2008; Kufe 2008). Phosphorylation 
of Tyr within the TDRSPYEKV sequence by c-Src and Lck stimulates interactions 
between MUC1 and β-catenin whereas phosphorylation of Ser by GsK-3β inhibits this 
interaction (Ren, Li et al. 2002; Ren, Bharti et al. 2006). The same Tyr residue is 
critically important for nuclear localization of MUC1, apparently because of the 
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requirement for tyrosine phosphorylation to support the appropriate interactions 
necessary for intracellular trafficking. Binding to β- catenin appears to provide the 
signals required for movement of MUC1 to the nucleus in tumor cells (Carson 2008) 
thereby influencing transcription through TCF/LEF and/or other transcription factors 
(Hollingsworth and Swanson 2004).  
We have generated mouse models of PDA in a congenic C57BL/6 background 
that either expresses human MUC1 (Tinder, Subramani et al. 2008) or genetically lacks 
Muc1. Cell lines have been developed from these mice to study the oncogenic role of 
MUC1 in pancreatic cancer progression. In this study, we show that EMT and secondary 
metastasis was significantly reduced in PDA mice that lack Muc1 compared to PDA mice 
that express MUC1. In contrast, over expression of MUC1 in both human and mouse 
pancreatic cancer cells initiated EMT by inducing the transcription factors, Snai1 and 
Slug and repressing E-Cadherin which lead to increased invasion and metastasis. 
Furthermore, mutating the tyrosines in MUC1 CT to phenylalanine completely blocked 
EMT and prevented metastasis. The data suggests direct oncogenic signaling through the 
tyrosines in MUC1 CT in the induction of EMT and metastasis during pancreatic cancer. 
3.3 Materials and methods 
Mouse Model 
            PDA mice was generated in our laboratory on the C57BL/6 background by 
mating the P48-Cre with the LSL-KRASG12D mice (Hingorani, Petricoin III et al. 2003) 
and further mated to the MUC1.Tg mice to generate PDA.MUC1 mice (Tinder, 
Subramani et al. 2008; Mukherjee, Basu et al. 2009) or to the Muc1KO mice (Spicer, 
Rowse et al. 1995) to generate PDA.Muc1KO mice (Figure 1A). Primary tumors were 
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dissociated using collagenase II and several lines of cells generated in our laboratory. 
These cells are designated KCKO for cells lacking Muc1 and KCM for cells expressing 
human MUC1. 
Invasion Assays 
            Cells were serum-starved for 48hrs prior to plating for the invasion assay. Cells in 
serum free media (50,000 cells) were plated over transwell inserts (BD Biosciences) pre-
coated with reduced growth factor matrigel or no matrix (control), and were permitted to 
invade towards serum contained in the bottom chamber for 48 hours. Non-invaded cells 
were swabbed from the tops of half of the inserts ('samples', containing only invaded 
cells), and retained in the others ('controls', all cells). Inserts were stained for 10 minutes 
with crystal violet (0.5% in 20% methanol) and washed with water. Membranes were 
destained for 10 minutes in 10% acetic acid and absorbance read at 570 nm. Percent 
invasion was calculated as absorbance of samples/absorbance of controls × 100. 
Western Blots and Antibodies 
          Briefly, cells were lysed in HEPES buffer (20 mmol/L HEPES, 150 mmol/L NaCl, 
1% Triton X-100, 2 mmol/L EDTA) containing protease (Complete inhibitor cocktail; 
Roche, Indianapolis, IN) and phosphatase inhibitors (10 mmol/L sodium fluoride, 2 
mmol/L sodium vanadate, 50 µmol/L ammonium molybdate). Equal quantities of lysate 
were loaded on SDS-PAGE gels. MUC1 CT antibody CT2, was made in Mayo Clinic 
Immunology Core (Schroeder, Thompson et al. 2001). MUC1 TR (B27.29) antibody was 
acquired from Biomira Inc.,Edmonton, Alberta. All other antibodies (Snai1, Slug, N-
Cadherin, Vimentin, Vegf, E-Cadherin, Twist, β-catenin, and β-actin) were purchased 
from Santa Cruz Biotechnology, Santa Cruz, CA and were used according to 
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manufacturer's recommendations. Co-immunoprecipitation (co-IP) using CT2 (1:500 
dilution) and β-catenin (1:100 dilution) were carried out as previously reported (Al Masri 
and Gendler 2005) using 1mg of protein lysate prepared in 1% Brij buffer (Sigma) 
followed by standard western blotting. 
Cloning of MUC1 WT and MUC1 Y0 Vectors 
            MUC1 Y0 was created using the Quick Change mutagenesis kit (Stratagene, La 
Jolla, CA) (Thompson, Shanmugam et al. 2006). Briefly, primers based on the MUC1 
sequence were designed containing single-base alterations resulting in mutation of the 
tyrosine residues (Y) in MUC1 CT to phenylalanine (F) as shown schematically. 
 
Successful mutations were confirmed with DNA sequencing. MUC1 Y0 and MUC1 WT 
were cloned into the pLNCX.1 vector consisting of the neomycin resistance gene for 
retroviral infection. 
Cell Culture and Retroviral Infection  
             BxPC3 cells and Su86.86 (American Type Culture Collection, Manassas, VA) 
are two human pancreatic cancer cell lines that express very little endogenous MUC1.The 
cells were maintained in complete RPMI (Invitrogen, Carlsbad, CA) supplemented with 
10% FCS, 1% glutamax (Invitrogen), and 1% penicillin/streptomycin. For retroviral 
infection, GP2-293 packaging cells (stably expressing the gag and pol proteins) were co-
transfected with the full-length MUC1 construct or the Y0 construct or empty vector 
expressing the VSV-G envelope protein as previously described (Thompson, Shanmugam 
et al. 2006). After 48 hours, virus was pelleted; resuspended in medium containing 8 
 
Y=tyrosine; F=phenylalanine 
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µg/mL polybrene (hexadimethrine bromide) and incubated overnight with BxPC3 or 
Su86.86 cells that had been pretreated for 2 to 3 hours with polybrene. Cells were 
selected with 0.5 mg/mL G418, beginning 48 hours post infection, and cells were 
maintained as polyclonal populations until sorted. Two independent infections of the 
constructs were carried out with similar results. Expression of the constructs was stable 
throughout the span of experiments. Cells infected with vector alone were used as control 
and designated Neo. For MUC1 and Y0-infected cells, MUC1+ve cells were sorted using 
the FACSAria. For Neo-infected cells, MUC1-ve cells were sorted.  
Confocal Microscopy 
            Cells were plated on chamber slides and grown to the desired confluency.  Cells 
were washed, fixed in –20°C ethanol, permeabilized with 0.5% Tween 20 and stained 
with the appropriate primary (Santa Cruz Biotechnologies) and secondary antibodies 
(Invitrogen, Carlsbad, CA). Nuclei were stained with To-pro-3 (Invitrogen). For tumor 
sections, similar protocol was followed. Pictures were taken at 400X using confocal 
microscopy (Carl Zeiss International, Thornwood, NY). 
Real-time PCR in the Taqman low-density custom made array format       
             Total RNA was extracted according to standard protocol using the Qiagen 
RNeasy mini-kit protocol; (Invitrogen, Carson City, CA). cDNA was constructed using 
TaqMan® Reverse Transcription cDNA kit from Applied Bioscience (Foster City, CA). 
Each low-density custom array card was configured for 72 different genes in triplicates. 
The samples were distributed to the microwells by centrifugation for 1 min at 343 x g. 
The cards were sealed and placed in an ABIPRISM7900HT thermocycler for 40 cycles of 
95°C to 60°C. The SDS2.2 software was used for qualitative analysis. Arrays were 
 59 
performed independently at least three times for each cell line; values were obtained for 
the threshold cycle (Ct) for each gene and normalized using the average of four 
housekeeping genes on the same array (HPRT1, RPL13A, GAPDH, ACTB). Ct values for 
housekeeping genes and a dilution series of ACTB were monitored for consistency 
between arrays. Change (ΔCt) between BxPC3-neo, MUC1, and Y0 was found by: ΔCt = 
Ct (MUC1 or Y0) – Ct (neo) and fold change by: Fold change = 2(-ΔCt).Values are 
provided as fold change.  
Isolation of Nuclear Protein  
             Cells were washed once with ice cold 1x PBS and then resuspended in buffer A 
(10 mM HEPES pH 7.5, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA and 0.1% Nonidet-
P40) on ice. Lysate was then spun at 6000 rpm, 1min, 4°C and the resulting pellet was 
washed twice in 1x ice cold PBS before sonication in buffer B (20mM HEPES ph 7.9, 
25% glycerol, 400mM NaCl, 1.5mM MgCl2, 0.2mM EDTA, 0.5mM DTT) to obtain the 
nuclear fraction which was then spun at 13 000 rpm for 20min, 4°C, for western blot 
analysis using CT2 and β-catenin. 
In vivo tumor growth  
             Two-month old nude mice were injected with 5x106 (in 100ul of phosphate buffer 
saline) BxPC3 MUC1, BxPC3 Neo or BxPC3 Y0 into the flank of the mice. Tumors were 
allowed to grow for two months. Mice were palpated every second day starting at 7 days 
post tumor injection until sacrifice. Tumor weight was calculated according to the 
following formula: grams=(length in centimeters x (width)2)/2 (Simpson-Herren and 
Lloyd 1970). Upon sacrifice, the tumors were prepared for lysates, and fixed for 
immunohistochemistry (IHC). Serum was collected.  
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Immunohistochemistry 
              Tumors sections were formalin fixed in 10% neutral-buffered formalin (pH 6.8-
7.2) for a minimum of 24 hours. Paraffin embedded blocks were prepared by the 
Histology Core at The Mayo Clinic and 4-micron thick sections were cut for immuno-
staining. VEGF expression was determined using the Santa Cruz Biotechnologies 
antibodies at 1:50 dilution followed by the appropriate secondary antibody (1:100 
dilution, DAKO, Carpenteria, CA). Sections were developed using 3, 3”–
Diaminobenzidine as the chromogen and hematoxylin was used as the counterstain. 
Slides were examined under light microscopy and pictures taken at 400X magnification.  
Isolation of viable circulating human pancreatic cancer cells 
           Blood samples (0.5–1.0 ml) were obtained by cardiac puncture from individual 
tumor-bearing animals using heparin as the anticoagulant and processed immediately. 
Erythrocyte-free nucleated cell fractions were obtained using the RBC lysis by 
ammonium chloride solution according to the protocol supplied by the manufacturer 
(Stemcell Technologies, Inc., Vancouver, Canada). The erythrocyte-free nucleated cell 
fraction was immediately expanded in culture in DMEM complete media as previously 
described (Glinskii, Smith et al. 2003).  
Protein Array Assay 
             Tumor lysates were analyzed using The RayBio® Custom human cytokines and 
growth factor antibody array kit (RayBiotech, Norcross, GA).  Assay was conducted 
according  to  the  manufacturer’s  instructions (Das Roy, Pathangey et al. 2009).  
Chemiluminescence was detected using a  EpiChemi3® Darkroom  imaging  system  and  
LabWorks®  densitometry  software  (UVP  Bioimaging,  Upland,  CA).   Data was 
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corrected for background signal and normalized to positive controls using RayBio® 
Analysis Tool software. The protein analysis was done by the company.  
Proteomics:  
           For the electrophoretic separation of each sample, 30 ug of protein was loaded on 
a 10 % Bis-Tris NuPAGE gel (Invitrogen, Carlsbad, CA). The gel slices were digested 
with trypsin and analyzed.  A Nano Acuity UPLC system connected to an LTQ- Orbitrap 
hybrid MS system (Thermo Fisher, Pittsburg, PA) with Nanospray interface was used.. 
Data was acquired using Xcaliber (Thermo Fisher, Pittsburg, PA) and processed by using 
Bioworks software and mouse v.3.18 fasta database. SEQUEST parameters were used as 
follows: mass tolerance of 0.01 Da for precursor ions and 0.5 Da for fragment ions, 
variable modification on methionine of 16 Da, and maximum missed cleavage of 1. 
Search results were entered into Scaffold software (Proteome Software) for compilation, 
normalization, and comparison of spectral counts. Protein identifications were made at 
the peptide probability of 95 % and protein probability of 99 %. Experiments for Mass 
spectroscopy were duplicated for a power law global error model (PLGEM). Datasets 
were imported into R program for statistical computing. 
Densitometry analysis 
            The densitometry analysis of the western blots was performed using NIH 
provided software. Results were presented as arbitrary densitometry units corrected for 
background intensity.  
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Statistical analysis 
             Statistical analysis was performed with SPSS 10 software. P-value was generated 
using the one way Anova and significance was confirmed using the Duncan and Student-
Newman-Keul test. Values were considered significant if p < 0.05. 
3.4 Results 
PDA.MUC1 mice have significantly higher incidence of metastasis to the lungs, liver 
and peritoneum as compared to PDA.Muc1KO mice. This is characterized by 
increased Vimentin and decreased E-Cadherin in the primary pancreas tumors.  
            We have generated a model of spontaneous PDA that expresses human MUC1 as 
a self molecule (PDA.MUC1 mice) (Tinder, Subramani et al. 2008; Mukherjee, Basu et 
al. 2009). To further elucidate the role of MUC1 in PDA, we have also generated the 
PDA mice in a Muc1 null background (PDA.Muc1KO mice) (schematically represented 
in Figure 1A ). Mice were sacrificed at ~36-40 weeks of age when all mice had primary 
pancreatic tumors. However, when organs were evaluated for macroscopic lesions, sixty 
percent (8/13 mice) of the PDA.MUC1 mice developed lung metastasis with ~40% (5/13) 
developing liver and ~20% (3/13) developing peritoneum metastasis (Figure 1B). This 
was in contrast to PDA.Muc1KO mice where only 1 out of 10 mice developed metastasis 
in all three organs. To investigate the mechanism by which MUC1 initiated higher 
metastasis, we evaluated if MUC1 plays a role in activating the EMT-associated proteins 
in the primary pancreatic tumors. Tumor lysates from n=5 PDA.MUC1 and 
PDA.Muc1KO tumors were analyzed by proteomics analysis. Several proteins were 
differentially expressed; however, the most notable difference was in the levels of 
Vimentin and E-Cadherin.  In the PDA.MUC1 tumors, there was a significant increase 
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(5-fold) in Vimentin with concurrent decrease in E-Cadherin (Figure 1C). In contrast, the 
pattern was completely reversed in the PDA.Muc1KO tumors with significantly higher 
(4-fold) E-Cadherin levels and lower Vimentin levels (Figure 1D).  The data was the first 
indication of possible induction of EMT in the MUC1-expressing tumors. Repression of 
E-Cadherin and induction of Vimentin in the PDA.MUC1 tumors directly correlated with 
increased metastasis in the PDA.MUC1 mice.  
MUC1 promotes induction of mesenchymal markers and functionally enhances the 
invasive capacity of pancreatic cancer cells in vitro. 
             To further confirm the role of MUC1 in EMT, cells were isolated from 
PDA.Muc1KO mice (designated as KCKO cell line) and PDA.MUC1  mice (designated 
as KCM cell line). Expression of MUC1 was confirmed by western blotting (Figure 1E) 
using two monoclonal antibodies, one recognizing the extracellular tandem repeat 
domain (MUC1 TR) and the other recognizing MUC1 CT domain. As was expected, 
there was high expression of MUC1 in the KCM cells and no expression of MUC1 in the 
KCKO cells (Figure 1E). Both cell lines were subjected to an in vitro invasion assay, 
results of which showed significantly higher invasion index of the KCM cells compared 
to the KCKO cells (p<0.01, Figure1F), confirming MUC1 as the major contributor of 
increased motility and invasiveness. Furthermore, presence of MUC1 in KCM cells 
clearly repressed E-Cadherin expression (Figure 1D) and induced expression of 
transcription factors and proteins associated with the mesenchymal phenotype. These 
included Snai1, Slug, N-cadherin, and Vimentin (Figure 1G), which potentially 
contributed to the contact inhibition and high invasion in vitro and in vivo (Figure 1F and 
1B). Lastly, KCM cells expressed higher levels of vascular endothelial growth factor 
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(VEGF) compared to KCKO cells (Figure 1G), another indicator of highly metastatic 
phenotype. Thus, we hypothesized that MUC1 initiates EMT and induces invasion in 
mouse pancreatic cancer cells.  
Over expression of MUC1 in human pancreatic cancer cells promotes EMT and 
induces invasion: Role of tyrosines in the MUC1 CT.  
             To further test our hypothesis and delineate the potential mechanism, we stably 
infected human pancreatic cancer cell lines, BxPC3 and Su86.86 with full length MUC1 
or mutated MUC1 CT. Cells expressing full –length MUC1 was designated 
BxPC3.MUC1 and Su86.86.MUC1 while the ones expressing mutant MUC1 CT was 
designated BxPC3.Y0 and Su86.86.Y0. Cells infected with an empty vector containing 
the neomycin resistance gene were used as controls and designated BxPC3.Neo and 
Su86.86.Neo. Expression of MUC1 was confirmed in both cell lines by western blotting 
(Figure 2A –D) using both the MUC1 TR (B27.29) and MUC1 CT (CT2) antibodies. 
B27.29 antibody detects the high molecular weight fragment (>200 kD) and CT2 detects 
a low molecular weight fragment (<45kD). The small shift in electrophoretic mobility 
noted in the Y0 cell lysate relative to MUC1 cells likely reflects a decrease in 
phosphorylation due to the mutations of the tyrosine residues in the Y0 cells (Figure 2B 
and D). Several bands appear in the blot for the MUC1, which may represent differences 
in glycosylation or other post-translational modifications of this subunit.  
An in vitro invasion assay showed  significantly higher invasive index for the BxPC3 and 
Su86.86 cells expressing full length MUC1 as compared to the cells expressing Y0 or 
Neo (p<0.01, Figure 2E and F). These results suggest that the increased invasiveness of 
the MUC1-expressing cells may be attributed to the tyrosines in the MUC1 CT. To 
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substantiate the role of the MUC1 CT tyrosines as an inducer of EMT, real-time PCR 
arrays were used to explore transcription of 72 genes implicated in EMT and metastasis. 
In these experiments, only the BxPC3 cells were ustilized. Genes whose transcription was 
altered by at least 2-fold compared to Neo-cells were considered significant. Several 
genes associated with tight junctions and epithelial phenotype was significantly reduced 
in BxPC3-MUC1 cells compared to the Neo cells. These included Tight Junction Proteins 
1 and 3, Occludin, Laminin α5, β-and δ-catenin, Claudin, and E-cadherin (Figure 2G). In 
contrast, there was no such change in gene expression in the Y0 cells (Figure 2G). 
Conversely, genes associated with the mesenchymal phenotype and invasion/migration 
was significantly increased in the BxPC3 MUC1 cells compared to Neo cells. These 
included Vimentin, Twist, Slug, Snai1, and Goosecoid, (Figure 2H). Once again, the Y0 
cells had lower expression of the mesenchymal-associated genes (Figure 2H). Both 
functional and molecular studies indicate that MUC1 initiates the process of EMT via 
signaling through the tyrosines in its CT and that no external factor is necessary to 
stimulate these changes. It is rather interesting that while most of the epithelial cell-
associated genes remained unchanged between Neo and Y0, E-Cadherin and Claudin 
were significantly higher in the Y0 versus the Neo cells. Likewise, several of the 
mesenchymal associated gene transcription including Twist, Snai1, Goosecoid, and 
Fibronectin were significantly lower in the Y0 cells compared to Neo cells, implications 
of which are not yet known. 
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Loss of epithelial marker and gain of mesenchymal markers in BxPC3-MUC1 but 
not in Y0 cells directly corresponds to their in vitro invasive potential and metastatic 
gene expression. 
             At the protein level, gain of mesenchymal markers such as Slug, Snai1 and 
Vimentin and loss of E-cadherin expression was apparent in the BxPC3 MUC1 cells by 
western blot analysis even though the lysates were prepared from a heterogeneous 
population consisting of both the migrating and non-migrating cells (Figure 3A and B). 
Downregulation of E-cadherin was further confirmed by confocal microscopy 
(Figure3C). This was not the case with the BxPC3 Y0 cells implicating the importance of 
the tyrosines in MUC1 CT for effective oncogenic signaling and induction of EMT. It is 
well established that Snai1 represses the expression of E-cadherin and induces EMT in 
several cancer cells (Batlle, Sancho et al. 2000; Cano, Perez-Moreno et al. 2000; Guaita, 
Puig et al. 2002). Thus, taken together, the data clearly suggests a role for MUC1 in 
inducing EMT in human pancreatic cancer cell lines via signaling through its cytoplasmic 
tail tyrosines. Furthermore, genes associated with metastasis and angiogenesis such as 
VEGF, MMP-9, 3, & 2 and IL-6R were significantly increased in BxPC3-MUC1 but not 
in Y0 cells compared to Neo controls (Figure 3D). This confirms that EMT-linked 
phenotype such as repressed E-cadherin and increased Vimentin, Snai1, and Slug are 
associated with increased metastasis-associated genes. Thus, without the tyrosines, EMT 
and metastasis is blocked in human pancreatic cancer cells.  
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Circulating tumor cells (CTCs) detected in vivo with BxPC3-MUC1 but not with 
Neo or Y0 tumors.  
            To test tumor growth and metastasis in vivo, BxPC3-MUC1, Y0 and Neo cells 
were subcutaneously injected into nude mice. All cells formed tumors within 1 month of 
injection and the tumor growth was significantly higher in BxPC3 MUC1 as compared to 
BxPC3 Y0 and BxPC3 Neo cells (Figure 4A (*P<0.001)). Tumors were dissected two-
month post challenge and evaluated for presence of MUC1 by western blotting. MUC1 
TR (B27.29) and CT (CT2) antibodies were used and as was expected, BxPC3 MUC1 
and Y0 tumors expressed high levels of MUC1 while Neo tumors expressed negligible 
amounts of MUC1 (Figure 4B). Since we were unable to detect gross metastatic lesions 
in the nude mice because BxPC3 cells do not metastasize from subcutaneous tumors, we 
evaluated if there were CTCs in the blood of these mice. Within 2-weeks of culture, we 
were able to detect colonies of tumor cells in the blood collected from BxPC3-MUC1 but 
not from Neo or Y0 tumor-bearing mice (Figure 4C). The data signifies the role of 
MUC1 CT tyrosines during pancreatic cancer growth and extravagation of the cells into 
the blood stream for future metastasis. 
Detection of EMT in vivo in BxPC3-MUC1 tumors 
             Protein lysates from the tumors were analyzed for the epithelial and 
mesenchymal markers. Similar to the in vitro data in Figure 3, the BxPC3 MUC1 tumor 
lysate showed downregulation of E-Cadherin (Figure 4D) and upregulation of Slug, 
Snai1, and Vimentin (Figure 4E). The data clearly indicates the initiation of EMT in vivo 
in only the MUC1-expressing BxPC3 tumors and this process was completely abrogated 
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when the tyrosines were mutated even though high levels of MUC1 protein was being 
expressed in the Y0 tumors (Figure 4B).  
Significantly higher levels of pro-metastatic and pro-angiogenic growth factors in 
the BXPC3 MUC1 tumor microenvironment compared to Y0 or Neo tumors.  
            To determine the effect of EMT on the tumor microenvironment itself, we tested 
the protein levels of some of the known mediators of metastasis and angiogenesis in the 
tumor lysates using the Ray Biotech protein array kit. Significant increase in levels of 
circulating VEGF (10-fold), insulin-like growth factor-1 (IGF-1, 2-fold), interleukin-6 
(IL-6, 3-fold) and its receptor (IL-6R, 2.2-fold), stem cell factor (SCF, 2.5 fold), P-
selectin (20-fold), and epidermal growth factor (EGF, 2.8-fold) were observed in the 
BxPC3-MUC1 tumors (Figure 4F) compared to the Neo and Y0 tumors. VEGF 
expression was also determined by IHC in the tumor sections with high levels detected in 
the BxPC3 MUC1 tumors versus Neo and Y0 tumors (Figure 4G).These results are novel 
and speak to the critical signaling role of the tyrosines within the MUC1 CT during 
oncogenesis. It is striking that simply abrogating the signal transduction events by 
mutating the seven tyrosines can completely reverse the process of EMT and significantly 
alter the tumor microenvironment, subsequently leading to a less aggressive, less 
metastatic, and less angiogenic phenotype. Lysates from n=3 mice were tested and 
average fold-increase is shown (Figure 4F). Two-fold or more increase was considered 
significant and is represented. Thus, BxPC3 MUC1 xenografted tumors exhibited an 
aggressive phenotype consistent with the human tumors that express high MUC1. This 
included loss of E-cadherin, induction of Vimentin and upregulation of metastatic and 
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angiogenic factors. The loss of tyrosine residues in MUC1 CT completely abrogated the 
entire process of EMT and metastasis.  
MUC1 interacts with β-catenin and translocates to the nucleus in the BxPC3-MUC1 
cells.  
           To delineate the underlying mechanism by which the Y0 tumors circumvent EMT, 
we tested the nuclear localization of MUC1 CT and β-catenin in the MUC1 and Y0 cells.  
It is known that tyrosine residues in MUC1 CT are critically important for nuclear 
localization of MUC1 CT. Previous reports have demonstrated that MUC1 CT tyrosine 
phosphorylation is required to support interaction of MUC1 with β-catenin which is 
necessary for intracellular trafficking (Hollingsworth and Swanson 2004) and possibly 
EMT. Thus, nuclear extracts from BxPC3 MUC1 and Y0 cells were analyzed for 
presence of MUC1 and β-catenin. Although β-catenin was present in the nuclear extracts 
in both cells, the levels were significantly higher in BxPC3 MUC1 cells compared to the 
Y0 cells (Figure 5A). Similar results was obtained with the KCM and KCKO cells where 
higher levels of β-catenin were detected in the nuclear extract of the KCM versus the 
KCKO cells (Figure 4B). More importantly, although both BxPC3 MUC1 and Y0 cells 
contained equal levels of MUC1, there was no detectable MUC1 CT in the nuclear 
extract of the Y0 cells while high levels was detected in the BxPC3 MUC1 cells (Figure 
5A). The results were substantiated in Su86.86 MUC1 and Y0 cells (Figure 5C). The data 
clearly suggests that signaling through the tyrosines is critically important for efficient 
nuclear translocation of MUC1 CT and β-catenin. Purity of the nuclear extract was 
confirmed by the presence of lamin and the absence of IKK (Figure 5A-C).  
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Since tyrosine phosphorylation is also required for MUC1 to bind β-catenin and 
translocate to the nucleus, we examined if β-catenin and MUC1 co-IP in these cells. β-
catenin pulled down MUC1 only in the BxPC3-MUC1 cells but not in the Y0 cells 
(Figure 5D). Similarly, MUC1 pulled down β-catenin more effectively in the BxPC3-
MUC1 cells as compared to Y0 cells. Non-specific pull down was not detected using an 
IgG control antibody (data not shown). The co-IP of β-catenin and MUC1 was confirmed 
in the KCM and KCKO cells and in the Su86.86 cells (Figure 5E and F).  Thus, we 
confirm that binding of MUC1 to β-catenin appears to provide the signal required for 
movement of MUC1 to the nucleus and that the tyrosines in MUC1 CT have to be 
functional for the two proteins to interact. Note: Neo cells were not included in these 
experiments as they express minimal levels of endogenous MUC1. 
3.5 Discussion 
 Although it is known for decades that MUC1 is aberrantly over-expressed in 
greater than 65% of PDA and is associated with poor prognosis and metastasis, its precise 
role has remained obscure. We show for the first time in both mouse and human 
pancreatic tumors that 1) over-expression of MUC1 initiates the process of EMT and 
augments metastasis and 2) lack of tyrosines in the CT of MUC1 abrogates this process.  
The first evidence of EMT came from the proteomics data showing repression of E-
Cadherin and induction of Vimentin expression in the PDA.MUC1 tumors when 
compared to the PDA.Muc1KO tumors. This correlated with significantly higher 
incidence of secondary metastasis in PDA.MUC1 mice as compared to the 
PDA.Muc1KO mice. The PDA mice are unique in that the pancreatic tumors arise 
spontaneously in an appropriate tissue background, within a suitable stromal and 
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hormonal milieu, and in the context of a viable immune system (Hingorani 2003; 
Hingorani, Petricoin III et al. 2003; Tinder, Subramani et al. 2008; Mukherjee, Basu et al. 
2009). The tumor progression and the histopathology of the tumors in the PDA mice 
mimic the human disease with the initial development of pancreatic intra-epithelial 
neoplastic (PanIN) lesions progressing to carcinoma-in-situ (CIS), and invasive 
adenocarcinoma. The process of EMT and increased invasiveness in MUC1-expressing 
pancreatic tumors was confirmed in cell lines generated from the PDA mice and 
validated in two human pancreatic cell lines. The underlying molecular mechanism in all 
cell lines pointed to the induction of transcription factors, Snai1, and Slug which 
stimulated the expression of N-Cadherin and Vimentin and repressed E-Cadherin 
expression. E-Cadherin plays a key role in the establishment and maintenance of adherent 
junctions and loss of the same results in contact inhibition and cell motility. Interestingly, 
the molecular process of EMT was completely abrogated when all seven tyrosines in the 
CT of MUC1 were mutated to phenylalanine.  Recent evidence shows that the 
phosphorylation of the tyrosines in the MUC1 CT are critical for the binding of β-catenin 
to MUC1 CT and that the MUC1 CT-β-catenin complex can be tranlocated to the nucleus 
to render its oncogenic signal (Wen, Caffrey et al. 2003). We show that lack of tyrosines 
in the MUC1 CT regulates the complexing of MUC1 CT with β-catenin and therefore its 
efficient translocation to the nucleus (Figure 5). It is also known that β-catenin binds to 
the SXXXXXSSL motif in the CT of MUC1 (Yamamoto, Bharti et al. 1997) and changes 
in tyrosine phosphorylation of MUC1 CT correlate with differences in cell adhesion 
(Yamamoto, Bharti et al. 1997; Quin and McGuckin 2000). Thus, we can speculate that 
the underlying mechanism for EMT might be the requirement of the tyrosines adjacent to 
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the β-catenin binding domain (possibly at the TDRSPYEKV site) to be phosphorylated. 
C-src and PKCδ have been shown to phosphorylate the tyrosines at that site and increase 
the interaction between β-catenin and MUC1 (Li and Kufe 2001; Ren, Li et al. 2002). We 
therefore propose that MUC1 may directly influence the transcriptional co-activator 
status of β-catenin, and up-regulate several genes that are associated  with EMT such as 
Snai1, Slug, Twist, Vimentin and Goosecoid (Figure 2D) possibly through interactions 
with TCF/LEF1 and/or other transcription factors. Snai1 in turn represses E-cadherin 
message and protein levels in MUC1-expressing cells (Figures 1-4), perhaps through 
direct binding to the three E-boxes in the E-cadherin promoter (Guaita, Puig et al. 2002). 
E-cadherin plays a key role in the establishment and maintenance of adherent junctions, 
repression of which leads to down regulation of Tight Junction Proteins 1 and 3, 
Occludin, Laminin α5, and β-and δ-catenins (Figure 2C). Dissolution of pancreatic 
epithelial cell junctions is hence brought about by a concerted activation of mesenchymal 
proteins and repression of epithelial proteins in vitro and in vivo leading to EMT and 
metastasis exemplified by the presence of CTCs in BxPC3.MUC1 tumors (Figure 4C) 
and enhanced metastasis in the PDA.MUC1 mice (Figure 1B). 
              These molecular changes lead to an in vivo microenvironment in the MUC1 
tumors favoring increased angiogenesis, and pro-inflammatory cytokines (Figure 4F and 
G), leading to increased metastasis. The glycoprotein P-selectin, an adhesion molecule 
involved in the initiation of the inflammatory process and induction of other pro-
inflammatory cytokines such as IL-6 and its receptors (Kaikita, Ogawa et al. 1995; 
Dymicka-Piekarska, Matowicka-Karna et al. 2007) is increased by 20 fold in MUC1 
tumors versus the Neo tumors (Figure 4F). In addition, link between IL-6R and 
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angiogenic cytokines such as VEGF has been shown in several cancers (Alexandrakis, 
Passam et al. 2003), with VEGF being a potent inducer of angiogenesis and promoter of 
tumor progression (Justinger, Schluter et al. 2008). VEGF is increased by 10-fold in the 
MUC1 tumors versus the Neo tumors (Figure 4F). Like P-selectin, SCF is also a member 
of a group of glycoprotein growth factors designated hematopoietic cytokines (HCs) 
known to affect the growth of pancreatic cancer (Mroczko, Szmitkowski et al. 2005). 
SCF is increased in the MUC1 tumors by 2.5 fold compared to Neo tumors (Figure 4F). 
Finally, IGF-I and EGF signaling induces growth and proliferation in pancreatic cancer 
cells (Bardeesy and DePinho 2002) (Wolpin, Michaud et al. 2007), and is increased by 2 
and 3 fold  respectively in MUC1 versus the Neo tumors (Figure 4F). Importantly, 
simultaneous targeting of both IGF-1 and EGF receptors has lead to enhanced antitumor 
activity (Lu, Zhang et al. 2005). Thus, it is indeed striking that the significant induction 
of all the above factors in the MUC1 tumors versus the Neo tumors was completely 
abrogated when the tyrosines in the MUC1 CT was deemed non-functional in the Y0 
tumors (Figure 4F). This once again signifies the critical requirement of the MUC1 CT 
tyrosines in pancreatic cancer oncogenesis and metastasis.  
           The regulation of MUC1 CT phosphorylation and parameters that affect its 
association with β-catenin are not fully understood, although interaction of MUC1 with 
ErbB1 (Schroeder, Thompson et al. 2001) has been shown to enhance the binding 
between c-src, β-catenin and MUC1 (Hollingsworth and Swanson 2004) and increase 
ERK1/2 phosphorylation and NFκB activation (Schroeder, Thompson et al. 2001; 
Thompson, Shanmugam et al. 2006). Preliminary data from our laboratory shows that the 
active form of NFκB (p65 subunit) is significantly lower in Y0 cells compared to the 
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MUC1-expressing BxPC3 and Su86.86 cells (unpublished data). It has also been reported 
that phosphorylation of MUC1 CT by src, ErbBs, and PKCδ regulates its association with 
β-catenin and GSK-3β (Li, Kuwahara et al. 2001; Li, Ren et al. 2001; Ren, Li et al. 2002; 
Kohlgraf, Gawron et al. 2003). Another critical study demonstrates that met-mediated 
phosphorylation of MUC1 modulates signaling related to motility and invasion in 
pancreatic cancer (Singh, Behrens et al. 2008). Our study exemplifies the functional 
consequences (EMT and metastasis) of signaling through MUC1 CT, and for the first 
time delineates the role of MUC1 in a unique mouse model of PDA that lacks Muc1.  
          This study defines the role of MUC1 signaling (through its CT tyrosines) in the 
initiation of EMT perhaps by β-catenin-MUC1 interaction and translocation to the 
nucleus, leading to activation of the EMT-associated transcription factors Snai1 and Slug. 
This in turn enables the tumors to acquire a highly aggressive phenotype creating a pro-
metastatic microenevironment in vivo. Future studies will focus on identifying the 
particular tyrosine/s within MUC1 CT and determining if inhibiting its phosphorylation 
using small molecule kinase inhibitors may lead to a novel treatment modality for 
pancreatic cancer. 
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3.6 Figures 
 
Figure 1: PDA mice lacking Muc1 has significantly lower incidence of secondary 
metastasis associated with decreased induction of EMT proteins in the tumors. 
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A. Schematic representation of PDA, PDA.MUC1 and PDA.Muc1KO mice. PDA mice 
were mated to the human MUC1.Tg and mouse Muc1 KO mice to get PDA.MUC1 mice 
and PDA.MUC1 KO mice respectively. B. Percent mice that developed metastasis in 
PDA.MUC1 versus PDA.MUC1 KO mice. C and D. Proteomics data on PDA.MUC1 
and PDA.Muc1 KO tumor lysates showing E-cadherin repression and Vimentin 
upregulation. E. Western blot analysis of MUC1 expression for KCM and KCKO cells 
using  MUC1 TR and MUC1 CT monoclonal antibodies. F. Transwell invasion assay 
showing significantly higher invasion index for KCM cells compared to KCKO cells 
(*P<0.001). G. Gain of mesenchymal proteins in KCM cells versus KCKO cells. β-actin 
serves as control for equal protein loading. 
 
Figure 2:  Significantly higher invasion and transcription of genes associated with a 
mesenchymal phenotype coupled with significantly lower transcription of genes 
associated with an epithelial phenotype in MUC1 over-expressing human pancreatic 
cancer cells as compared to control cells. Complete reversal in the MUC1.Y0 expressing 
cells.C1 expression by western blot analysis: A. MUC1 TR and B. MUC1 CT staining of 
BxPC3 Neo, MUC1, and Y0; C. MUC1 TR and D. MUC1 CT staining of Su86.86 Neo, 
MUC1, and Y0. >200kDa represents MUC1 TR domain and <45kD represents MUC1 
CT domain. β-actin was used as loading control. E - F. In vitro trans-well invasion assay 
for BxPC3 and Su86.86 cells respectively; Compared to Neo and Y0 cells, MUC1-
expressing cells have significantly higher invasion index (* p<0.001). G - H. RT-PCR 
analysis of BxPC3 Neo, MUC1, and Y0 cells: G. Transcription of genes generally 
associated with epithelial phenotype. H. Transcription of genes generally associated with 
mesenchymal phenotype. Genes whose transcription was altered by at least 2-fold or 
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more were considered significant. Average fold change is shown from three separate 
experiments. All experiments were repeated 3-5 times. Clones from three independent 
infections were analyzed with similar results. 
 
 
Figure 3: Repression of E-Cadherin and induction of Snai1, Slug, and Vimentin in 
BxPC3 MUC1 cells coupled with significantly increased transcription of genes associated 
with metastasis. Complete reversal in MUC1-Y0 expressing cells. A and B. Western 
blotting analysis of Slug, Snai1, Vimentin, and E-Cadherin expression in BxPC3 Neo, 
MUC1, and Y0 cells. C. Immunofluorescence staining and confocal microscopic image 
of E-Cadherin levels in BxPC3 Neo, MUC1 and Y0 cells. Images were taken at 400X 
magnification. The experiments were repeated 3 times with three separate clones with 
similar results. β-actin was used as loading control. D. RT-PCR analysis of genes 
generally associated with metastasis and angiogenesis. 2-fold or more difference was 
considered significant. Average fold change is shown from three separate experiments.  
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Figure 4: Higher tumor burden with loss of E-Cadherin and gain of mesenchymal and 
metastatic proteins in BxPC3 MUC1 versus Y0 and Neo tumors.  
A. In vivo tumor growth in nude mice. Significantly higher tumor burden in BxPC3. 
MUC1 versus Neo and Y0 tumors (*p < 0.001). B. MUC1 expression by western blotting 
using the MUC1 TR and CT antibodies C. Tumor cells cultured from whole blood of 
tumor-bearing mice. Circulating tumor cells detected in the blood of mice bearing the 
BxPC3 MUC1 but not BxPC3 Y0 or Neo tumors. D. Expression of E-Cadherin in 
primary tumors by western blotting. E. Expression of Slug, Snai1, and Vimentin in 
primary tumors by western blotting. F. High levels of pro-metastatic and pro-angiogenic 
proteins detected in the BXPC3 MUC1 tumor lysate. Fold change in levels of various 
factors in BxPC3 MUC1 tumor lysate compared to Y0 and Neo, G. Expression of VEGF 
by IHC. Images were taken at 400X magnification. Similar results with n=3 mice were 
obtained. 
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Figure 5: MUC1 interacts with β-catenin and translocates to the nucleus in the MUC1-
expressing cells. Complete reversal in the Y0 cells. 
Protein expression of MUC1 CT and β-catenin in the nuclear extracts of A. BxPC3 
MUC1 and Y0; B. KCM and KCKO and C. Su86.86  MUC1 and Y0 cells. Lamin and 
IKK used as positive and negative control for nuclear extracts. Co-IP of MUC1 CT and 
β-catenin in both directions from D. BxPC3 MUC1 and Y0; E. KCM and KCKO  and F. 
Su86.86 MUC1 and Y0 cells.  
CHAPTER 4: MDSCS 
 
 
4.1 Myeloid Derived Suppressor Cells (MDSC) 
             Tumor associated immune suppression: In recent years, new developments have 
been raised in the concept of cancer treatment in which the immune system is recruited in 
order to clear the transformed tumor cells. Studies have shown that cancer patients are 
capable of inducing expansion of tumor reactive CD4+ and CD8+ T-cells in their lymph 
nodes and peripheral blood in response to tumor associated antigens (Schmitz-
Winnenthal FH 2005; Schmitz-Winnenthal FH 2006). Infiltration of lymphocytes to the 
site of tumor progression can be associated with a better prognosis in cancers such as 
breast, colon, esophageal, and ovarian cancer. (Yoshimoto M 1993; Naito Y 1998; 
Reichert TE 1998; Yasunaga M 2000; Strater J 2005; Sato E 2005 ).  
              However, presence of tumor infiltrating lymphocytes does not clear the tumor 
mass. In fact, the tumor microenvironment has been shown to be a site of ongoing 
inflammation and immune suppression. Presence of inflammatory cytokines and immune 
suppressive cells in the tumor microenvironment is well established (as reviewed in 
(Gordon S 2010)). It is believed that expression of some of the tumor derived soluble 
factors and inductions of regulatory cells are one of the major means by which tumor 
cells escape the anti-tumor immune response. Due to these factors, the elicited immune 
response whether through targeted immune therapy or through natural processes, is not 
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protective. Successful translation of immune therapy into a treatment option is dependent 
on reversal of the suppression of anti tumor immune response.  
4.2 Functions of MDSCs 
            Myeloid Derived Suppressor Cells (MDSCs) were identified over 20 years ago 
when Young et al reported that bone marrow cells from tumor bearing mice can inhibit 
T-cell clonal activation (Young 1987). MDSCs are a heterogeneous population of cells 
which have originated from the myeloid cells in the bone marrow. Tumors can 
aggressively draft a network of regulatory cells such as MDSCs to weaken the anti tumor 
immune response in a local and systemic fashion. MDSCs are immature cells with a 
significant ability to repress T-cell responses. These cells expand under pathological 
conditions such as cancer progression, infection, sepsis, and trauma.  
             In the bone marrow of healthy individuals, common myeloid progenitor cells 
quickly differentiate into dendritic cells (DCs), Macrophages, or granulocytes. During 
cancer progression, cancer cells, activated T-cells and stromal cells express factors such 
as Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) (Obermueller E 
2004), IL-6 (Trikha M 2003), Stem Cell Factor (SCF) (Melani C 2003), IL-1β, 
Prostaglandin E2 (PGE-2), and Vascular Endothelial Growth Factor (VEGF) (Bunt SK 
2006; Tinder 2008). These factors and cytokines are known to influence hematopoiesis 
(Obermueller E 2004) and prevent maturation and differentiation of common myeloid 
progenitor cells into their destined cell type. This results in expansion of immature 
myeloid cells which under the influence of tumor derived factors gain suppressive ability 
and are eventually known as MDSCs (Figure 1). 
 82 
 
 
 
 
 
 
 
 
 
 
 
 
Figure1. MDSC expansion. Under pathological conditions, altered hematopoiesis results 
in decreased differentiation of myeloid cells and causes expansion of MDSCs.   
 
 
            Both in humans and mice accumulation of MDSCs has been observed in the bone 
marrow, spleen, blood, draining lymph nodes and tumor (Almand B 2001; Mirza N 2006; 
Ochoa AC 2007; Tinder 2008; Diaz-Montero CM 2009) . In addition, MDSCs are 
invariably associated with metastasis (Diaz-Montero CM 2009). Taken altogether, this 
has led scientists to link the presence of activated MDSCs to cancer-associated immune 
suppression and increased metastasis.   
           As mentioned, MDSCs are a heterogeneous population of cells and in mice are 
defined as cells which co-express Gr1 and CD11b (Gabrilovich DI 2007). The antibody 
which recognizes Gr1 can in fact recognize two different epitopes: Ly6C and Ly6G. 
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Phenotypically, MDSCs are divided into the granulocytic (CD11b+LY6G+LY6Clow) and 
the monocytic (CD11b+LY6G-LY6Chigh) subsets (Hestdal K 1991; Youn 2008) which are 
proposed to have different functions during cancer and infection (Dietlin ta 2007; Zhu B 
2007; Movahedi K 2008). A small portion of MDSCs are shown to form myeloid 
colonies and about 30% can differentiate into DCs and macrophages (Bronte 2000). 
4.3 MDSC expansion 
             Many pathological conditions can induce MDSC expansion. Bacterial and 
parasitical infections as well as polymicrobial sepsis induce increased MDSC levels. 
Several studies have focused on identifying factors which can provoke MDSC expansion. 
It appears that activated immune system is one of the major factors which can cause these 
cells to expand. Such expansion is always associated with altered hematopoiesis. Type, 
tissue, and origin of the tumor can influence MDSC expansion. Below, we are going to 
introduce and briefly explain some of the prominent factors which are known to either 
alter hematopoiesis and cause MDSC expansion, or can act directly on MDSCs and 
activate them during tumor development. These factors can originate from the tumor 
cells, stromal cells, or activated T-cells.  
 
• GM-CSF: Several groups have shown that high doses of Granulocyte-
Macrophage Colony Stimulation Factor (GM-CSF) administration induce 
transient post-vaccine suppressive MDSCs and fail to induce anti tumor immunity 
in tumor bearing mice (Bronte 2000). GM-CSF dependent MDSC induction leads 
to both CD4 and CD8+ T-cell suppression which hampers post vaccine immune 
response (Fu 1990; Young 1991; Bronte V 1999).  
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• G-CSF: Tumor infiltrating MDSCs have both macrophage and neutrophilic 
phenotype. Lack of Chemokine Receptor-2 (CCR2) causes conversion of the 
macrophage phenotype to the neutrophile phenotype, indicating that excessive 
production of Granulocyte-Colony Stimulation Factor (G-CSF) causes induction 
of MDSCs with a neutrophilic characteristic (Sawanobori, Ueha et al. 2008). 
• M-CSF: Macrophage Colony Stimulation Factor (M-CSF) expression by of 
tumor cells influences DC maturation and instead induces MDSC expansion 
(Cheng 2008).  
• Prostaglandins: MDSCs express receptors for prostaglandins. EP2 deficient mice 
have been shown to have delayed tumor growth which is associated with 
decreased MDSC accumulation. Moreover, treatment of tumor bearing mice with 
a Cox-2 inhibitor resulted in reduced tumor burden associated with decreased 
MDSC levels indicating a significant role for Prostaglandins in MDSC expansion 
(Sinha 2007). Furthermore, Cox-2 mediated PGE-2 production induces T-cell 
suppressive activity in MDSCs, leading to a more immunosuppressive tumor 
microenvironment (Rodriguez 2005). 
• IFN-γ : Interferon gamma (IFN-γ) expression during cancer induces suppressive 
activity of MDSCs as well as its expansion (Gallina G 2006). IFN-γ and IL-3 
together can activate the metabolic pathways which lead to activation of MDSC 
suppressive function. 
• C5a: Complement proteins are found on tumor tissue suggesting local 
complement activation. MDSCs are known to express Complement component -
5a (C5a) receptors (Guo 2005) and accumulation and/or migration of MDSCs is 
 85 
found to be regulated by complement components such as C5a (Markiewski 
2008).  
• SCF: One of the functions of MDSCs is induction of T-cell anergy. Blocking 
SCF function has been shown to reverse T-cell anergy. Further, blockage of SCF 
enhances tumor vaccine therapeutic function. Indeed, studies have revealed that 
SCF inhibition causes decreased MDSC function and suppressive outcome which 
can account for increased effectiveness of anti tumor immune response (Pan PY 
2008).  
• S100A8 and S100A9: Under pathological conditions, calcium binding proteins 
like S100A9 are shown to be required for MDSC generation (Cheng 2008). 
S100A9 regulates suppressive activity of MDSCs via ROS. MDSCs also 
synthesize S100A8/9 while express receptors for S100 proteins to which they 
chemotact (Sinha, Okoro et al. 2008).  
• TGF-β: While transforming growth factor-beta (TGF-β) is known to 
downregulate antitumor immunesurveillance, CD1d restricted T-cells induce IL-
13 production which in turn increases TGF-β expression and induce 
immunosuppression via MDSCs in tumor bearing mice (Terabe 2003).  
• IL-1β: Tumor cells express substantial amounts of IL-1β. This inflammatory 
cytokine is known to both increase tumor burden and decrease survival time. This 
phenomena is associated with rapid induction of highly suppressive MDSCs 
(Bunt, Sinha et al. 2006). The effects of IL-1β on expansion of MDSCs are very 
strong and in fact, removal of the primary source of IL-1β (tumors) does not 
reverse levels of MDSCs.  
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• IL-6: According to epidemiologic studies, inflammation and especially chronic 
inflammation has long been associated with cancer initiation and progression. IL-
6, a well known inflammatory factor which is an IL-1β downstream cytokine, can 
alter MDSC expansion and function and consequently tumor progression (Bunt, 
Yang et al. 2007). In lack of IL-1β, IL-6 can fully restore MDSC expansion and 
function under tumor progression.  
• IL-10:  IL-10, a known Th2 cytokine with strong immunosuppressive function 
has been shown to induce MDSCs. IL-10 production during cancer progression 
induces MDSC function which causes T-regulatory cell suppressive activity 
(Huang B 2006).  
• IL-13: Perhaps one of the most important Factors which induces MDSC 
expansion and suppressive function is IL-13. While the source of IL-13 during 
cancer progression is a subject of debate, its role in MDSC induction is well 
established. MDSCs can respond to IL-13 in a both autocrine and paracrine 
manner and significantly suppress CTL generation and contribute to tumor 
progression (Gallina G 2006).  
 
These factors can alter signaling pathways responsible for differentiation and cell 
survival during hematopoiesis. STAT-3 signaling pathway which causes cell proliferation 
and survival is one of the first pathways which gets activated in myeloid progenitor cells 
under the influence of TDSFs and causes MDSC expansion (Bromberg 2002). STAT3 
activation causes increased levels of CyclinD1 and MYC expression to induce survival 
and proliferation and prevent maturation of myeloid progenitor cells (Nefedova 2004).  
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4.4 MDSC suppressive activities  
            Expansion of MDSCs is carefully regulated by the body. In fact, increased levels 
of MDSCs do not always mean immunosuppression. Induction of MDSC activity is 
another regulatory step taken by the immune system to ensure proper immune responses 
during infection, cancer, or trauma. Several studies have shown that along with MDSC 
expansion, TDSFs can induce MDSC activation to cause its suppressive function. 
Activated T-cells in patients suffering from infection or cancer produce high levels of 
IFN-γ which causes MDSC activation. Aside from inflammatory cytokines, MDSCs can 
sense stress and become suppressive.  
              TLRs are a family of proteins which are expressed on MDSCs and are known to 
regulate MDSC activity. TLR’s role in innate immune response and pathogen perception 
is very well studied. During cancer, tumor cells shed exosomes or undergo apoptosis 
which cause Heat Shock Proteins (HSP) containing membrane bound cell parts to be shed 
to the bloodstream and reach MDSCs to stimulate TLR signaling (Delano 2007). TLR 
activity whether through interaction with microbial parts or its endogenous ligands such 
as heat shock proteins (HSPs) has been linked to MDSC suppressive activity and 
expansion in the spleen (Van Rompaey and Le Moine 2011; Zoglmeier, Bauer et al. 
2011). Lack of MyD88, the adaptor for TLR, abrogates MDSC expansion indicating the 
regulatory role of TLR signaling in MDSC activity (Delano 2007). Furthermore, TLR 
activity in MDSCs induces IL-4, IL-13, or TGF-β expression. MyD88 signaling and 
cytokines induce signaling pathways which leads to NF-κB activity in MDSCs and 
ultimately causes immune suppression (Delano 2007).  
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            MDSC suppressive mechanisms: MDSCs have been shown to exert their 
suppressive ability through both cell-cell contact dependent and independent manner. 
These cells use a variety of mechanisms to induce immune suppression via decreasing T-
cell functionality. Various mechanisms have been described which include altering a) 
metabolism of amino acids necessary for T-cell function, b) T-cell receptor functionality, 
c) ROS production, and d) NK cell activity. These mechanisms are briefly explained 
below:  
• Arginase-1 expression: Arginase-1 is an enzyme which metabolizes L-arginine 
and converts it to urea and L-ornithine. Arginine is a conditionally necessary 
amino acid for humans. T-cell functionality and T-cell proliferation depends on 
availability if this amino acid (Rodriguez 2005). Exposure to Th2 cytokines such 
as IL-13, IL-4 (Munder 1998; Munder 1999), TGF-β (Boutard 1995), or GM-CSF 
(Jost 2003) cause MDSCs to express high levels of this enzyme which catabolizes 
L-arginine and causes decreased Arginine availability in the tumor 
microenvironment or the lymph node. Lack of L-arginine causes decreased CD3ζ 
expression on T-cells (Rodriguez PC 2002). CD3ζ is the key signal transducer 
element of the TCR and its proper function is crucial for proper T-cell activation. 
Further, following TCR stimulation, T-cells undergo clonal expansion and 
without L-arginine in the microenvironment, CyclinD3 and cyclin-dependent 
kinase-4 are not expressed. Therefore, due to expression of high levels of 
Arginase-1 by MDSCs, T-cell proliferation is strongly reduced in the tumor 
microenvironment (as reviewed in (Gabrilovich DI 2009).  
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• NO production: Nitric Oxide Synthase (NOS) family of proteins uses L-arginine 
as a substrate for its enzymatic activity. MDSCs are known to express high levels 
of iNOS which causes T-cell suppression through reduced Arginine levels 
(Rodríguez PC 2008). Moreover, activation of JAK1 and 3 pathways as well as 
ERK in T-cells is blocked in presence of NO due to iNOS activity (Bingisser RM 
1998). Furthermore, exposure of T-cells to NO causes T-cell apoptosis through 
Caspase independent pathway (Macphail 2003). Taken together, this means iNOS 
expression by MDSCs is one of the most potent ways to cause T-cell suppression. 
• Expression of peroxynitirite: peroxynitirite is a very strong oxidant and one of 
the essential intermediary elements which mediate T-cell suppression.  Following 
NO production, NO reacts with supreoxide anions to produce peroxynitirite. 
Peroxynitirite can then cause nitrosyalation and nitration of amino acids such as 
tryptophan, tyrosine, methionine, and cysteine. Through direct cell-cell contact 
between MDSCs and CD8+T-cells, peroxynitirite causes nitration of amino acids 
in the TCR and induces conformational changes in the TCR and alters its 3D 
structure and eventually leads to T-cell unresponsiveness in the tumor 
microenvironment (Vickers SM 1999; Bronte V 2005 ; Nagaraj 2007).  
• Induction of T-regs: IFN-γ derived from tumor specific T-cells in combination 
with IL-10 induce expression of cytotoxic lymphocyte antigen-4 in MDSCs which 
causes de-novo FoxP3 expression and T-reg cell induction. (Yang R 2006 ). Such 
event is linked to antigen specific T-cell suppression via MDSCs (Serafini, 
Mgebroff et al. 2008).   
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• ROS expression: In human and mice tumors, MDSCs have increased ROS 
production (Ribechini, Greifenberg et al. 2010; Zhang and Meadows 2010). 
Factors such as IL-6, IL-13, TGF-b, IL-10, PDGF, and GM-CSF can induce ROS 
expression by MDSCs and cause T-cell unresponsiveness (Sauer 2001)  
• NK cell inhibition: Natural Killer cells (NK cells) are very effective cells in 
clearing tumor cells and are an important member of the innate immunity which 
exert their cytotoxic effect on tumor cells and cause their death. Using several 
mouse models, MDSCs have been shown to decrease NK cell cytolytic 
functionality (Hoechst 2009; Li, Han et al. 2009; Elkabets 2010).  
 
            In addition to these mechanisms, different subsets of MDSC (monocytic and 
granulocytic) use different mechanisms to induce immune suppression. In most tumor 
models, it is the granulocytic subset that expands more (70-80%) and often uses ROS 
production as a suppressive mechanism (Youn 2008) and can modify the T-cell 
repertoire to induce antigen specific T-cell unresponsiveness. The monocytic subset 
expands to a smaller degree and induces suppression through NO expression (Youn 
2008) and within the tumor microenvironment can differentiate into F4/80+Gr1- Tumor 
Associated Macrophages (TAMs) (Gabrilovich 2005; Kusmartsev S 2005 ; Sica A 
2007). TAMs are alternatively activated macrophages which skew the immune response 
towards a TH2 type of response and are considered one of the biggest contributors to the 
immunosuppressive tumor microenvironment. MDSCs and TAMs can interact with each 
other and skew the immune response towards a Th2 type of response which results in 
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increased IL-10 production by MDSCs and decreased IL-12 expression by macrophages 
(P. Sinha 2007) which ultimately results in promotion of tumor growth. 
           MDSCs serve as a serious obstacle in the effectiveness of immunotherapy as a 
treatment option for cancer patients. Moreover, MDSCs can promote tumor growth, 
cancer progression, and metastasis. Since MDSCs induce immunosuppression through 
various means, it is tempting to assume that targeting them can eliminate various 
immunosuppression mechanisms and allow immunotherapy to be an effective way to 
target tumor cells.  However, targeting an entire cell population which happens to be 
heterogeneous is not an easy task. It is more practical to study key regulators of MDSC 
suppressive function and target them.  
            While MUC1 is known to be an epithelial cell marker, its expression and 
function on hematopoietic cells has been described (Agrawal B 1998; Treon 1999; Li 
2004; Mukherjee P 2005). We have previously shown that in Muc1 null mice, altered 
DC differentiation leads to increase MDSC expansion in response to GM-CSF and IL-4 
in-vitro (Poh, Bradley et al. 2009). Our study has revealed that Muc1 expression on 
hematopoietic cells acts as a signaling molecule to control MDSC expansion via 
stabilization of β-catenin and preventing aberrant expansion of MDSCs. Further, 
adoptive transfer of MDSCs from Muc1KO mice to WT mice challenged with allogeneic 
tumor resulted in tolerance to that tumor indicating that MDSCs from KO mice are more 
suppressive than that of WT mice. The mechanism and reason behind such observation 
was not studied.  
In our current study, we investigated MDSC expansion, differentiation, and suppressive 
function in WT and Muc1 null mice under cancer conditions. Using two models of 
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epithelial originated cancers (PDA and Breast Cancer), we have shown that not only 
Muc1KO mice have higher levels of MDSC expansion in the spleen, but that these 
MDSCs are more suppressive compared to that of WT mice. The fact that MUC1 can act 
as a regulatory mechanism to prevent increased MDSC expansion is of great importance 
since systemic targeting of MUC1 in many carcinomas is being actively explored. From 
our studies, it becomes clear that therapeutic targeting of MUC1 must be localized to the 
epithelial tumors because down-regulating MUC1 expression in hematopoietic cells may 
be harmful and lead to increased MDSCs. 
4.5 Results 
Hematopoietic Stem Cells (HSCs) and MDSCs express Muc1.  
           Previously, MUC1 expression on hematopoietic cells has been described (Agrawal 
B 1998; Treon 1999; Li 2004; Mukherjee P 2005). We wanted to know if MUC1 is 
expressed on HSCs. Through flow cytometry, we found that 100% of HSC cells from 
C57/B6 mice express Muc1 indicating that Muc1 may play a role in hematopoiesis 
(Figure 2A). Further, since functionality of MDSCs from Muc1 null mice is altered (Poh 
TW 2009), we hypothesized that immature myeloid cells (IMCs) express Muc1. In-fact, 
we have shown that a high percentage of IMCs express Muc1-CT indicating that Muc1 
possibly directly regulate MDSC function (Figure 2B). More interestingly, our data 
shows a significant decrease in Muc1 expression on MDSCs as cancer progresses 
indicating that increased suppressive function of MDSCs may be associated with 
decreased Muc1 expression by these cells.  
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MDSC expansion under cancer progression in the BM of Muc1 null mice is not 
different from that of WT mice.  
           To study whether Muc1 expression on HSCs leads to differential expansion of 
MDSCs in the bone marrow of cancer bearing mice, freshly isolated BM cells were 
analyzed for co-expression of Gr1 and CD11b.  We found that Muc1KO mice have 15% 
higher levels of MDSCs in the BM indicating that Muc1 may regulate ontogeny of these 
cells. Further, while we detected a significant induction of BM-MDSCs in mice injected 
with a pancreatic cancer tumor cell line (KCKO), we did not find any difference in the 
levels of MDSCs between tumor-bearing WT and Muc1KO mice (Figure 3A). In 
contrast, the breast tumor cell line, C57MG, completely failed to induce MDSC 
expansion in the BM. 
            To further characterize the BM-MDSCs from WT and Muc1KO mice, levels of 
Arginase and iNOS expression were studied via flow cytometry. Our results indicate that 
higher percent of MDSCs from healthy non-tumor-bearing Muc1KO mice express iNOS 
(Figure 3B) than its WT counterpart. Moreover, MDSCs from KCKO tumor-bearing 
Muc1KO mice express higher levels of iNOS than WT mice suggesting a more 
suppressive phenotype in Muc1KO MDSCs compared to WT MDSCs (Figure 3B). With 
regards to Arginase-1 expression on MDSCs, although tumor induced higher levels of 
Arginase-1 on MDSCs, there was no difference between WT and Muc1KO MDSCs 
(Figure 3C). Data on Arginase-1 expression is presented as MFI since all MDSCs 
appeared positive for Arginase expression.  
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BM-MDSCs from Muc1KO mice have a less differentiated phenotype compared to 
WT-MDSCs.  
            To check whether MDSCs from WT and Muc1KO mice differ in their 
differentiation/maturation state, we checked for Stem Cell Antigen-1 (Sca1), a stem cell 
marker known to be expressed on early MDSCs which are not close to terminal 
differentiation (Zoglmeier, Bauer et al. 2011). Our data demonstrates that under cancer 
condition not only a higher percentage of BM-MDSCs from Muc1KO mice are positive 
for Sca1 (Figure 3D), but also the levels of Sca1 expression was higher in BM-MDSCs 
from these mice signifying that these MDSCs are in a less differentiated stage compared 
to WT BM-MDSCs (Figure 3D). We then checked levels of c-MYC expression on 
MDSCs and found that under cancer condition, BM-MDSCs from Muc1KO mice express 
significantly higher levels of c-MYC than the WT MDSCs. C-Myc protein is responsible 
for MDSC survival (as reviewed in (Nagaraj and Gabrilovich 2007)). Our data suggests 
that BM-MDSCs in the absence of Muc1 are more likely to survive and proliferate and 
probably have a longer life span (Figure 3F).  
MDSC expansion and migration to the spleen of cancer bearing Muc1KO mice is 
higher than that of WT mice.  
           Spleen is the first major lymphatic organ to which MDSCs migrate to exert 
suppressive function prior to infiltrating tumors. To study whether Muc1 regulates 
MDSC expansion and migration to the spleen of tumor bearing mice, splenocytes from 
these mice were analyzed for Gr1+CD11b+ cells. According to our results, KCKO cells 
induced significant expansion/migration of MDSCs in the spleen and this expansion was 
significantly higher in the Muc1KO versus the WT mice (Figure 4A). In the breast cancer 
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model, C57MG cell line failed to induce MDSC expansion in the spleen of WT mice; 
however, in the Muc1KO mice, higher levels of Gr1+CD11b+ cells were detected 
compared to non-tumor bearing Muc1KO and tumor-bearing WT mice (Figure 4B). Our 
results indicated that increased migration and expansion of MDSCs in the spleen of 
Muc1KO versus WT mice.  
MDSCs from the spleen of Muc1KO tumor bearing mice are more suppressive 
compared to WT MDSCs.  
          We hypothesized that differential expression of suppressive enzymes in BM-
MDSCs might cause spleen MDSCs to be more effective in T-cell suppression. Using a 
Mixed Lymphocyte Reaction (MLR), we co-cultured MDSCs from WT and Muc1KO 
mice (bearing C57MG tumors) with naïve syngeneic T cells stimulated with α-
CD3/CD28 antibody and collected the supernatants to test for IL-2 production. Our 
results show that MDSCs from the spleen of cancer bearing Muc1KO mice were more 
effective in inducing T-cell suppression indicated by lower IL-2 production (Figure 4C). 
Thus, Muc1 regulates the suppressive function of MDSCs under cancer conditions.  
          To further study the mechanism behind increased MDSC suppressive activity in 
Muc1KO mice, we studied whether levels of suppressive enzymes were any different in 
MDSCs from Muc1KO versus WT mice. Our results show increased Arginase-1 
expression in the MDSC of Muc1KO and WT mice bearing the KCKO tumor compared 
to non-tumor bearing mice. However, there was no difference between levels of 
Arginase-1 expression between WT and Muc1KO mice (Figure 4D, E). No difference 
was detected in the levels of iNOS expression as well (data not shown). 
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            We then hypothesized that even though Arginase-1 expression in KO and WT 
MDSCs is not different; it is possible that its activity is different. Since Arginase-1 
converts L-arginine to urea, we tested the levels of urea production by Gr1+CD11b+ cells 
sorted from the spleen. For the KCKO model, male mice were used and for the C57 
model, female mice were injected with cancer cells. To our surprise, we found that 
Arginase-1 in MDSCs from healthy male Muc1KO mice are significantly more active in 
metabolizing Arginine indicating a more suppressed phenotype in Muc1KO mice. In 
healthy female Muc1KO mice, we saw a similar trend which was not statistically 
significant (Figure 4F, G).  However, we found that under cancer progression in both 
models, the levels of urea in MDSCs from tumor-bearing Muc1KO mice were 
significantly higher than its WT counterpart (Figure 4F, G). In agreement with our 
hypothesis, our data indicate that Muc1 regulates MDSC suppressive functions. Increased 
Arginase1 activity in Muc1KO MDSCs explain the reason behind decreased T-cell IL-2 
production observed in Figure 3C. Next, since TGF-β expression by MDSCs is known to 
be associated with induction of MDSC suppression activity, we measured levels of TGF-
β production by sorted MDSCs from WT and Muc1KO mice. Amazingly, our results 
show that MDSCs from healthy Muc1KO mice express significantly higher levels of 
TGF-β, indicating again a more suppressive phenotype even in Muc1KO MDSCs (Figure 
4H). Breast cancer progression caused increased production of TGF-β in both WT and 
Muc1KO mice and while there is a trend of increased TGF-β production by Muc1KO 
MDSCs, the difference was not statistically significant. We further analyzed cytokine 
secretion from Splenic MDSCs and found that IL-6 secretion in both tumor bearing and 
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healthy Muc1KO MDSCs is significantly higher than that of WT mice signifying the 
increased inflammatory function of these cells (Figure 4H).  
             Overall, our results have provided evidence supporting the hypothesis that Muc1 
not only regulates MDSC expansion, but also regulates MDSC suppressive function in 
both healthy condition and during cancer progression.  
Muc1KO mice have higher levels of TGF-β  but not IL-6 in their serum.  
               Due to higher levels and suppressive function of MDSCs in Muc1KO mice, and 
the inflammatory nature of these cells we wanted to know whether these mice express 
higher levels of TGF-β or IL-6. Serum from tumor-bearing and healthy mice was 
analyzed for certain cytokines known to induce MDSC expansion and are secreted by 
MDSCs. Our results show that in both cancer models, levels of TGF-β are significantly 
higher in Muc1KO mice (Figure 5A, B). We did not detect any differences in IL-6 levels 
in the serum of these mice (Figure 5C, D). Overall, our results show that during cancer 
progression, Muc1KO mice have higher levels of the immunosuppressive cytokine, TGF-
β circulating in the serum. Although the source of increased production of this cytokine is 
not known to use, its increase is known to influence MDSC expansion and function.  
Muc1KO mice are more susceptible to tumor growth.  
            Increased MDSCs cause susceptibility to tumor growth. In our study, a 
comparison of tumor growth and final wet weight between WT and Muc1KO mice 
indicate that in the absence of Muc1, mice are more susceptible to tumor growth with 
both KCKO and C57mg cell lines. In fact, not only tumors grow at a significantly faster 
rate in Muc1KO mice (Figure 6A, C), but tumors from WT mice never match the weight 
of that of Muc1KO mice (Figure 6B, D).  
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Muc1KO mice have decreased NK cell cytotoxicity.  
          As mentioned before, one of the suppressive functions of MDSCs is reducing NK 
cell cytotoxic activity. Therefore, we hypothesized that due to increased MDSC 
expansion and function, NK cells from Muc1KO cancer bearing mice are not as effective 
in inducing cell death. NK cells from the spleen of WT and KO mice with KCKO were 
sorted and incubated with Yac1 cells. Indeed, our results show that in the absence of 
Muc1, NK cells have decreased cytotoxic activity.  
4.6 Conclusion 
         MDSCs are a heterogeneous population of cells which expand under pathological 
conditions such as cancer and have an extraordinary ability to reduce antitumor immune 
response. Furthermore, MDSCs pose a significant problem to effectiveness of cancer 
immunotherapy. The underlying mechanism in regulation of MDSC expansion and 
function is not yet clear. 
              In this study, for the first time we have shown that Muc1 affects hematopoietic 
differentiation. Both increased levels of IMCs in the BM of Muc1KO mice, as well as 
increased levels of c-MYC expression by IMCs show that Muc1 regulates terminal 
differentiation of hematopoietic cells. Most interestingly, our findings show that MDSCs 
express Muc1 and this expression is significantly reduced as the tumor develops. 
Decreased Muc1 expression by MDSCs was associated with increased expansion and 
suppressive functions of these cells. Consistent with our data, Muc1 null mice have 
MDSCs which exhibit both a less differentiated phenotype (Figure 3D), and express 
higher levels of suppressive enzymes (Figure 3B). Injecting Muc1Ko mice with tumor 
cells resulted in increased tumor burden (Figure 6A-D) which is partially explained by 
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higher suppressive functions of their MDSCs (Figure 4C). Increased expansion of 
MDSCs from Muc1KO mice was also associated with decreased NK cell functionality 
(Figure 5E). NK cells play an important role in induction of innate immune response 
against cancer cells and their decreased cytotoxic function can in part explain the reason 
for increased susceptibility of Muc1KO mice to tumor growth.  
            Although, the mechanisms by which Muc1 regulates hematopoiesis are not fully 
elucidated, its role in regulation of STAT3 is well studied. STAT3 signaling is one the 
most important signaling pathways which induces MDSC expansion and suppression. It 
is tempting to speculate that in the absence of Muc1, STAT3 signaling is not carefully 
regulated and therefore these mice have such immunosuppressed phenotype. In fact our 
preliminary data suggests that in the absence of Muc1, MDSCs in the spleen have higher 
levels of p-STAT3. Also, we have previously shown that BM progenitor cells from 
Muc1Ko mice differentiate into Gr1+CD11b+ cells under GM-CSF/IL-4 (Poh TW 2009).  
We showed that in lack of Muc1, β-catenin stability in myeloid progenitor cells is 
reduced and therefore, altered Wnt signaling contributes to aberrant expansion of Muc1.   
           Our data show that in future, targeting MUC1 as a tumor antigen must be carefully 
reviewed. It is possible that blindly targeting MUC1 in cancer patients may also target 
MUC1 on MDSCs and induce its expansion and suppressive function. Most likely, novel 
tolls must be designed to only target tumor associated MUC1 on epithelial cells and not 
MUC1 on hematopoietic cells.  
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4.7 Materials and methods 
Cell line 
               PDA cell line called KCKO was generated by our lab. Pancreas was dissociated 
using collagenase and protease. Single cell suspension was plated in DMEM containing 
10% FBS. Several passages were passed and Pancytokeratin levels were checked to 
ensure purity of the cells. C57MG breast cancer cells were a kind gift from Dr. Gendler, 
Mayo clinic. All cell lines were maintained in DMEM (Invitrogen, Carlsbad, CA), 
10%FCS, 1%penicillin/streptomycin and 1%glutamax (Invitrogen). All cell types were 
maintained in 5% CO2 and 95% humidity. 
Mice 
            For this study, 3 month old C57/B6 and Muc1KO mice were used. For the PDA 
model, 106 KCKO cells were injected in the right flank of the mouse. For the breast 
cancer model, 106 C57MG cells were injected in the right low mammary fat pad. Tumors 
were allowed to grow and their volume was measured using a caliber every two days 
until mice were euthanized.  
Flow cytometry 
          5*105 cells were collected and labeled with fluorescent dye conjugated antibodies. 
Acquisition was performed by BD FACS Calibur and BD Fortessa.  Data was analyzed 
using FlowJO (Ashland, OR).  
MDSC Suppression Assay 
           CD3+T-cells were isolated from healthy C57/B6 mice using a Miltenyi kit 
(Miltenyi Biotec, Auburn, CA). Round bottom plates were coated with 10µg of 
functional α-CD3 antibody (eBiosciences, San Diego, CA) and 5 µg α-CD28 antibody 
 101 
overnight. 105 CD3+T-cells were plated in RPIMI containing 10% heat inactivated FCS, 
1%penicillin/streptomycin and 1%glutamax (Invitrogen). MDSCs were sorted first by 
enriching the CD11b+ cells from the spleen and then sorted for Gr1+cells using a 
Miltenyi kit. 105 MDSCs were incubated with CD3+T-cells for 72 hours. Supernatants 
were collected at 72hrs and were then subjected to IL-2 ELISA assay (eBiosciences).  
Arginase assay 
            2*105 MDSCs were subjected to Arginase activity assay. Briefly, cells were lysed 
with 1% Trition-X in 37ºC. 25mM Tris-HCl and 10mM MnCl2 was added to samples. 
Lysates were then heated in 56º to activate Arginase-1. 0.5M L-arginine was added to the 
lysates and the reaction was stopped using phosphoric and suphoric acid. 40 ul of a-
isonitrosopropiophenone was added and samples were heated at 95ºC for 30 minutes. 
Samples were read at 450 nm.  
ELISA 
           Levels of cytokines were analyzed using sandwich ELISA. IL-6 in the serum was 
analyzed using purified and biotynilated Ab from BD (Franklin Lakes, NJ). TGF-β in the 
serum of from MDSC sups were analyzed using a kit from eBioscience.  
Antibodies 
           Fluorescent antibodies against Gr1 (Miltenyi), CD11b (BD), iNOS (BD), 
Arginase-1, c-MYC (SantaCruz biotech, Santa Cruz, CA), Sca1 (Stem cell technologies, 
Vancouver, Canada) were used at a concentration of 1µg/sample.  
NK cytotoxicity assay 
            Untouched NK cells were isolated form splenocytes using the NK cell isolation 
kit (Miltenyi, Cat# 130-090-864) and assessed for NK cell cytotoxic activity against the 
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NK cell-sensitive target cell line, YAC-1.  1 x 107 YAC-1 cells were incubated in RPMI 
with 500µCi 51Cr (Perkin-Elmer Analytical Sciences) for 1 hour at 37°C and then 
washed with PBS. Target cells were adjusted to 105 cells/mL and 100µL (104 cells per 
well) were plated in a 96-well V-bottom plate.  NK cells were incubated with YAC-1 
target cells at decreasing effector:target ratios for 4 hours at 37°C in a total volume of 
200µL. The plate was again centrifuged at 1400 rpm for 8 minutes and then 30µL of 
supernatant was collected and counted on a gamma counter.  Spontaneous release from 
labeled target cells was determined incubated in medium alone, while maximal release 
was obtained from labeled target cells lysed with 10% TritonX. The following formula 
was used to calculate the percentage of YAC-1 cells lysed:  Percent specific cytotoxicity 
= [(experimental release - spontaneous release) / (maximal release - spontaneous release)] 
× 100. 
Statistical analysis 
            Statistical analysis was performed with GraphPad software. P-values were 
generated using the one way Anova and significance was confirmed using the Duncan 
and Student-Newman-Keul test. Values were considered significant if p < 0.05. 
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4.8 Figures 
 
 
Figure 2. Both HSCs and MDSCs express Muc1. A) Fresh BM cells from healthy mice 
were isolated and labeled with fluorescent Abs against Sca1 and Muc1-CT. B) BM cells 
from WT mice and WT mice with C57MG tumor were labeled with fluorescent 
antibodies against Gr1, CD11b, and Muc1-CT. samples were analyzed via flow 
cytometry. First, cells were gated on Gr1-CD11b and then analyzed for Muc1-CT 
expression. Representative i) dot-plot, ii) histogram and iii) bar graph is shown (***, 
P<0.0001) 
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Figure 3: MDSC phenotype in the BM of WT and Muc1KO mice.  A) BM cells from WT 
and Muc1Ko mice were isolated and labeled with Abs against Gr1 and CD11b. samples 
were analyzed via flow cytometry. (*, P<0.05) B) BM cells were gated on Gr1+CD11b+ 
cells and then analyzed for %cells which express iNOS. (*, P<0.05; **, P<0.01) C) BM 
cells were analyzed via flow cytometry for the level of expression of Arginase-1. (**, 
P<0.001). D, E) BM cells were gated on Gr1+CD11b+ and then were analyzed for 
expression of Sca1. Data is presented as both % cells which express Sca1 (D) and the 
levels of Sca1 expression (E) (* P<0.05; ** P<0.001). F) BM cells were gated on 
Gr1+CD11b+ markers and were then analyzed for the levels of c-MYC expression. Data 
is shown in bar graph, histogram, and dot-plot (* P<0.05) 
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Figure 4. MDSC phenotype and function in the spleen of WT and Muc1KO mice. A) 
Splenocytes were isolated from WT and Muc1KO mice and immediately labeled with 
fluorescent antibodies against Gr1 and CD11b. representative contour plot is shown. B) 
Gr1+CD11b+ cells were isolated from the spleen on C57MG tumor bearing mice and 
incubated with naïve CD3+T-cells which were stimulated by α-CD3/28 antibody. 1*105 
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MDSCs and 1*105 CD3+T-cells were co-cultured for 72 hours. Supernatant was analyzed 
via ELISA for production of IL-2. (*, P<0.01) C,D) Splenocytes were gated on 
Gr1+CD11b+ cells and analyzed for expression of Arginase-1. (*** P<0.0001). E.F) 
Sorted MDSCs were subjected to an Arginase-1 activity assay. Cell lysates were exposed 
to Arginine and urea production was measured (*, P<0.01; **, P<0.01; *** P<0.0001). 
G) TGF-β and IL-6 production by MDSCs from WT and Muc1KO mice injected with 
C57MG cells was analyzed through ELSIA.  
 
 
 
 
Figure 5. Inflammatory cytokine production by WT and Muc1Ko mice with cancer. A,B) 
Serum of WT and KO healthy and cancer bearing mice were subjected to ELISA to 
measure TGF-β and C,D) IL-6 production. (**, P<0.001; ***, P<0.0001). 
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Figure 6: Muc1KO mice are more susceptible to tumor growth compared to WT mice. A) 
3 month old male BK6 and Muc1KO mice were injected subQ with 106 KCKO cells 
(PDA cells). Tumor was measured every two days. B) Final tumor wet weight of WT and 
Muc1Ko mice with KCKO on day 23. B) 3 month old female WT and Muc1KO mice 
were injected in the mammary fat par with C57MG mice. Tumor volume was measured 
every 2 days. C) Final tumor wet weight of WT and KO +C57MG. D) NK cells were 
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isolated from the spleen of WT and Muc1KO KCKO bearing mice. NK cells were 
incubated with Yac1 cells and their cytotoxic ability was measured by a chromium 
release assay.  
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